US Pat. No. 10,335,549

DEVICES, SYSTEMS AND METHODS FOR MEDICAMENT DELIVERY

kaleo, Inc., Richmond, V...

1. An apparatus, comprising:a housing;
a medicament container disposed within the housing
a plunger having distal end configured to move within the medicament container between a first position and a second position in repsonse to a first force;
a needle coupled to the medicament container, a portion of the needle configured to be disposed outside of the housing;
a needle sheath covering the needle; and
a sheath retainer removably coupled to the housing such a portion of the sheath retainer is disposed within the housing, the sheath retainer configured to be disposed about at least a portion of the needle sheath, the sheath retainer including a grip surface including a grip protrusion configured to receive a second force to move the sheath retainer in a distal direction relative to the housing, the sheath retainer including a retaining tab that engages the needle sheath and is configured to exert at least a portion of the second force against the needle sheath when the sheath retainer is moved in the distal direction, the portion of the second force removing the needle sheath from about the needle when the sheath retainer is removed from the housing in the distal direction, the sheath retainer including a lock protrusion configured to engage the housing to resist movement of the sheath retainer in the distal direction, an outer surface of the sheath retainer including an indicium indicating an order of operation for removal of the sheath retainer.

US Pat. No. 10,335,548

SYRINGE ASSEMBLY

Cinti Medical, Inc., Tem...

1. A syringe assembly, comprising:a barrel, the barrel is arranged about a longitudinal axis and is fitted internally with a head of a plunger, an inner plug, an outer plug, and a framework, the head, the inner plug, the outer plug, and the framework are each arranged about the longitudinal axis of the barrel, the head, the inner plug, and the outer plug are engaged slidably to the barrel, a first chamber in the barrel for containing a first component is between the head of the plunger and the inner plug, a second chamber in the barrel for containing a second component is between the inner plug and the outer plug, a third chamber in the barrel is between the outer plug and a discharge end of the barrel, and the framework is collapsible and is in the third chamber;
the head slides along the barrel and moves through the first chamber to against the inner plug for driving the first component from the first chamber between the barrel and the inner plug and into the second chamber for initially mixing the first component with the second component in the second chamber, when the plunger is plunged along the barrel toward the inner plug from an initial position of the head to a first position of the head;
the head and the inner plug concurrently slide along the barrel and the inner plug moves through the second chamber to against the outer plug for driving the first component and the second component from the second chamber between the barrel and the outer plug and into the third chamber, when the plunger is plunged along the barrel toward the outer plug from the first position of the head to a second position of the head; and
the head, the inner plug, and the outer plug concurrently slide along the barrel and the outer plug moves through the third chamber collapsing the framework between the outer plug and the discharge end for turbulent mixing the first component and the second component in the third chamber into a solution and for injecting the solution through the discharge end of the barrel from the third chamber, when the plunger is plunged along the barrel toward the discharge end from the second position of the head to a plunged position of the head;
wherein the first component is one of a solvent and a solute, and the second component is the other one of the solvent and the solute.

US Pat. No. 10,335,547

METHOD AND APPARATUS FOR CLOSED-LOOP CONTROL OF NERVE ACTIVATION

PURDUE RESEARCH FOUNDATIO...

1. An apparatus for activating one or more neurons in a patient at a desired activation level for a therapeutic purpose comprising:a transducer for stimulating the one or more neurons according to a set of stimulus parameter values;
a measuring electrode configured to measure an activation level yielded by the stimulation of the one or more neurons, the activation level representing at least one of (1) a percentage of activated neurons inside a nerve, (2) a percentage activation of organ function, or (3) a percentage inhibition of organ function;
a neuron activation comparator for comparing the measured activation level of the one or more neurons to the desired activation level of the one or more neurons; and
a closed-loop micro controller configured to autonomously predict, at a microprocessor, a particular set of stimulus parameter values to apply to form a stimulation pulse shape yielding the desired activation level representing a particular non-zero percentage of a particular non-zero percentage of at least one of (1) activated neurons inside a nerve, (2) organ function, or (3) inhibition of organ function,
the closed-loop micro controller is configured to autonomously derive the predicted set of stimulus parameter values to apply from measured patient characteristics,
the closed-loop micro controller is configured to autonomously generate an activation profile of one or more neuron types based on a measured physiological response to the stimulation according to the predicted set of stimulus parameter values,
the generated activation profile comprises, for each of two or more particular non-zero activation levels of each of the one or more neuron types, a plurality of sets of stimulus parameter values observed or predicted to yield the particular non-zero activation level,
the closed-loop micro controller is configured to autonomously derive the measured patient characteristics via a linear regression from at least one of (1) measurements by the measuring electrode of the activation level of each of the one or more neuron types for different electrical pulse durations and amplitudes and (2) measurements of organ function for different electrical pulse durations and amplitudes,
the closed-loop micro controller is configured to actively maintain the desired activation level at the particular non-zero percentage by adjusting the predicted set of stimulus parameter values to apply to stimulate the one or more neurons,
the closed-loop micro controller applies changes to the activation profile of the one or more neuron types over time based on the adjusted set of stimulus parameter values and is configured to adapt to the changes in the activation profile of the one or more neuron types to maintain the desired activation level by autonomously updating the measured patient characteristics based on at least one of (1) additional measurements by the measuring electrode of the activation level of each of the one or more neuron types for different electrical pulse durations and amplitudes and (2) additional measurements of organ function for different electrical pulse durations and amplitudes.

US Pat. No. 10,335,546

APPARATUS FOR OPTIMIZING A PATIENT'S INSULIN DOSAGE REGIMEN

Hygieia, Inc., Ann Arbor...

1. An apparatus for improving a patient's insulin dosage regimen, comprising:at least one computer-readable memory for storing: programming instructions, data inputs corresponding at least to one or more components in the patient's insulin dosage regimen, and a patient's blood-glucose-level measurements determined at a plurality of times within a predefined period of time;
a timer for monitoring the predefined period of time, the timer being incremented based on at least one of: passage of a separate predetermined increment of time or receipt of at least one of the patient's of blood-glucose-level measurements;
a display operative to display information corresponding to at least the patient's insulin dosage regimen; and
a processor configured to communicate with the at least one computer-readable memory and to execute the programming instructions stored in the at least one computer-readable memory to cause the apparatus to perform a method comprising:
(i) determining a number that represents excessive hypoglycemic events within the predefined period of time;
(ii) determining, after obtaining at least one blood-glucose-level measurement but before obtaining a subsequent blood-glucose-level measurement, whether the obtained blood-glucose-level measurement reflects a hypoglycemic event or a severe hypoglycemic event;
(iii) reducing at least one of the one or more components in the patient's insulin dosage regimen in response to a determination that the obtained blood-glucose-level measurement represents a severe hypoglycemic event;
(iv) reducing at least one of the one or more components in the patient's insulin dosage regimen in response to a determination that the obtained blood-glucose-level measurements results in an excessive number of hypoglycemic events during the predefined period of time; wherein the timer is reinitiated after the determination that there have been an excessive number of hypoglycemic events over the predefined period of time; and
(v) determining, at the end of the predefined period of time, from a plurality of the data corresponding to the patient's blood-glucose-level measurements whether and by how much to vary at least one of the one or more components in the patient's insulin dosage regimen in order to maintain the patient's blood-glucose-level measurements within a predefined range; and
(vi) communicating the revised at least one of the one or more components in the patients insulin dosage regimen to the display to enable the patient's insulin dosage regimen to be updated on the display;
wherein the timer is reinitiated after the determination of whether and by how much to vary at least one of the one or more components in the patient's insulin dosage regimen.

US Pat. No. 10,335,545

TIME DEPENDENT DRUG DELIVERY APPARATUS

1. A drug delivery apparatus, comprising:a drug reservoir that stores a drug therein;
a temperature sensitive component that is at least one of the drug, the drug reservoir, or a power source that powers the drug delivery apparatus;
a temperature sensor in thermal communication with the temperature sensitive component to sense a temperature of the temperature sensitive component;
a transcutaneous device; a pump coupled to the transcutaneous device to deliver the drug via the transcutaneous device; and
processor that:
(i) receives from the temperature sensor an initial sensed temperature of the temperature sensitive component prior to initial delivery of the drug,
(ii) calculates a time delay for the temperature sensitive component to reach, starting from the initial sensed temperature, a predetermined working temperature that is between 100 C and 37° C., and
(iii) initiates initial delivery of the drug by the drug delivery apparatus following expiration of the calculated time delay, regardless of the temperature of the temperature sensitive component following expiration of the calculated time delay.

US Pat. No. 10,335,544

PASSIVE RESTART Y-SITE

CareFusion 303, Inc., Sa...

1. A fluid delivery Y-site device comprising:a body having a chamber, a primary flow port, secondary flow port, and an exit flow port fluidly coupled to the chamber;
a valve guide having a lower portion that extends into the chamber, between the primary flow port and the exit flow port, and an upper portion that extends from the lower portion toward the primary flow port;
a valve positioned in the chamber, between the primary flow port and the valve guide, wherein the valve is moveable between the primary flow port and the lower portion of the valve guide; and
a float positioned within the chamber between the valve and the exit flow port, wherein the float comprises a protrusion, and wherein the float is configured to move based on a level of fluid in the chamber, such that the protrusion of the float extends through the valve guide and engages the valve to occlude the primary flow port.

US Pat. No. 10,335,543

INSERTION DEVICE FOR AN INFUSION SET

TecPharma Licensing AG, ...

1. An insertion device for an infusion set, comprising:an advancement unit for moving the infusion set along a central axis of the insertion device from a proximal position of the insertion device into a distal position of the insertion device;
a retaining element for retaining the infusion set, wherein the retaining element comprises a guide element;
a base part accommodating the retaining element, wherein the base part comprises in a single component a mating guide element and a contact surface configured to be placed on an application point of a patient's body, the mating guide element being axially fixed relative to the contact surface; and
a head part rotatably coupled to the base part such that the head part and the base part are rotatable relative to one another about the central axis,
wherein the guide element of the retaining element is in a guiding engagement with the mating guide element of the base part and relative rotation between the head part and the base part in a first rotational direction causes the guide element of the retaining element to be rotatably guided with the mating guide element of the base part such that the retaining element rotates along the central axis relative to the base part from a distal position of the retaining element into a proximal position of the retaining element.

US Pat. No. 10,335,542

FLUID-CONNECTION MECHANISM AND METHODS FOR PATCH-PUMPS

SteadyMed Ltd., Rehovot ...

1. A method of delivering a drug, the method comprising:removing a pin from a patch-pump assembly to automatically cause a penetrator to penetrate a seal of a prefilled drug-reservoir, the patch-pump assembly comprising the penetrator, the prefilled drug-reservoir, a fluid-passageway, a cannula-containing assembly, and a spring-based mechanism;
flowing the drug from the prefilled drug-reservoir to the fluid-passageway;
establishing fluid communication between the fluid-passageway and the cannula-containing assembly using the spring-based mechanism;
flowing the drug from the fluid-passageway to the cannula-containing assembly; and
delivering the drug subcutaneously to a subject using the cannula-containing assembly.

US Pat. No. 10,335,541

PUMP CASSETTES WITH FLOW STOP AND INFUSION PUMP SYSTEMS

CareFusion 2200, Inc., S...

1. A pump cassette comprising: a rigid body comprising two opposing edge sections, an inlet port, an outlet port, and a controllable fluid pathway extending from the inlet port to the outlet port; a slider coupled to the two opposing edge sections and longitudinally articulable along the two opposing edge sections with respect to the rigid body; and a flow stop valve operably coupled to the controllable fluid pathway, wherein the flow stop valve is disposed on the rigid body such that longitudinal articulation of the slider along the two opposing edge sections causes a portion of the slider to actuate the flow stop valve, wherein the flow stop valve is configured to occlude fluid flow through the controllable fluid pathway when the slider is in a first position, and to allow fluid flow through the controllable fluid pathway when the slider is in a second position, wherein the flow stop valve comprises a striker portion coupled to a membrane portion, wherein the portion of the slider is configured to depress the striker portion to urge the membrane portion to occlude fluid flow through the controllable fluid pathway, wherein the striker portion comprises a piece attached to the membrane portion, wherein the portion of the slider is configured to contact the piece to depress the piece when the slider is in the first position, and wherein the piece is configured to align under a recess of the slider such that the slider does not contact the piece when the slider is in the second position.

US Pat. No. 10,335,540

PHARMACEUTICAL BLEND INFUSION THEREOF AND PARKINSON'S DISEASE MONITORING SYSTEM

MICREL MEDICAL DEVICES S....

1. A system for administering a drug to a Parkinson's disease patient comprising (a) a drug, (b) a storing bag for the drug, (c) a pump for administering the drug, and (d) a pump controller for controlling the pump activity,the pump controller having access to a correlation of a first parameter tx and a second parameter At, to a current first parameter tx, and to a mobility calendar indicating start and finish times for particular values of the first parameter tx,
wherein the first parameter tx is correlated with an activity level of the patient and the second parameter At is correlated with a dosage of the drug and the pump controller controls a flow rate of the drug based on changes of the first parameter tx scheduled in the mobility calendar of the first parameter tx and the correlation of the first parameter tx and the second parameter At; and
wherein the controller further has access to a parameter “b”, wherein the controller controls the pump activity in case of a change of the first parameter by a multiplication of parameter b with the difference between an adjusted second parameter At+z that is correlated with an adjusted first parameter t+z after the change and the second parameter At that is correlated with the first parameter tx before the change to amend the dosage z minutes prior to the change by adding the result of the multiplication b*(At+z?At) to the dosage according to the second parameter At, wherein z is the time delay of the drug action being constant for each different drug and infusion path.

US Pat. No. 10,335,539

DEVICES AND METHODS FOR MODULATING MEDIUM DELIVERY

Osprey Medical, Inc., Mi...

1. A method for mechanically modulating a fluid medium delivered to a vascular site within a body of a patient, the method comprising:employing a system including:
a sterile medium container that contains the fluid medium;
an injector;
a delivery catheter configured to deliver the fluid medium from outside the body of the patient to the vascular site within the body of the patient;
a chamber disposed between the injector and the delivery catheter;
a first connector, said first connector being fluidly coupled to each of the injector, the chamber, and a second connector, wherein the first connector is fluidly coupled to the chamber via a first valve;
the second connector being fluidly coupled to the sterile medium container via a second valve, and the second connector being fluidly coupled to the delivery catheter, wherein the second connector resides between the first connector and the delivery catheter;
injecting the fluid medium from the injector to the first connector, wherein the first valve is open;
simultaneously accepting a portion of the injected fluid medium into the chamber, wherein said chamber comprises at least one surface that imparts a force on the fluid medium within the chamber;
delivering the fluid medium to the vascular site within the body of the patient through the delivery catheter at a flow rate that remains substantially unchanged during the injecting of the fluid medium; and
drawing the fluid medium from the sterile medium container and filling the injector with the drawn fluid medium, wherein the first valve is closed and the second valve is open.

US Pat. No. 10,335,538

SYSTEM AND TREATMENT METHOD TO INCREASE CIRCULATION AND PLURIPOTENCY OF STEM AND PROGENITOR CELLS WITHIN A PATIENT

1. A treatment method to increase circulation and pluripotency of stem and progenitor cells within a patient by a practitioner, the method comprises the steps of:(A) providing a medicinal-administration system including a syringe, an infusion device, and a tourniquet;
(B) identifying an accessible peripheral vein on an upper extremity of the patient;
(C) preparing a volumetric dosage of an oxygen-ozone mixture within the syringe of the medicinal-administration system;
(D) applying the tourniquet to a cannulation area on the upper extremity and inserting the infusion device into the accessible peripheral vein of the patient before step (E);
(E) transfusing the volumetric dosage of the oxygen-ozone mixture from the syringe, through the infusion device, and into the accessible peripheral vein of the patient at a specified rate by releasing the tourniquet from the cannulation area during step (E) after the practitioner witnesses a flash of blood within the cannulation area;
(F) targeting a renal system and/or bone marrow of the patient with the volumetric dosage of the oxygen-ozone mixture to create stem and progenitor cells within the renal system and/or bone barrow of the patient; and
(G) repeating steps (B) through (F) as a plurality of treatment sessions.

US Pat. No. 10,335,537

INTEGRATED STRONTIUM-RUBIDIUM RADIOISOTOPE INFUSION SYSTEMS

Bracco Diagnostics Inc., ...

1. An infusion system on-board a cart comprising:a first shielding compartment having a first opening through which a strontium-rubidium radioisotope generator can be inserted into and removed from the first shielding compartment;
a first door configured to provide access to the first shielding compartment and to close over the first opening;
a second shielding compartment having a second opening through which a waste bottle can be inserted into and removed from the second shielding compartment;
a radioactivity detector positioned to measure radioactivity of a rubidium radioactive eluate flowing through an eluate tubing line in fluid communication with an outlet tubing port of the strontium-rubidium radioisotope generator;
a computer configured to receive an input from a user for controlling operation of the infusion system, wherein the computer is in electronic communication with a screen display;
a shielded detector compartment configured to receive the radioactivity detector; and
wherein the computer of the infusion system is configured to:
pump saline from a saline reservoir into the strontium-rubidium radioisotope generator through an inlet tubing port of the strontium-rubidium radioisotope generator thereby generating the rubidium radioactive eluate that is discharged through the outlet tubing port,
fill an eluate reservoir in a shielded well with a test sample to a predetermined volume,
receive a strontium breakthrough test result of the test sample filled into the eluate reservoir in the shielded well, wherein the strontium breakthrough test result of the test sample filled into the eluate reservoir in the shielded well is determined with a second radioactivity detector;
not allow a patient infusion if the strontium breakthrough test result is greater than or equal to an allowed limit;
measure a radioactivity of the test sample with the radioactivity detector while the test sample is flowing through the eluate tubing line to the eluate reservoir in the shielded well;
measure a calibration radioactivity of the test sample with the second radioactivity detector while the test sample remains in the eluate reservoir;
compare the radioactivity of the test sample measured by the radioactivity detector with the calibration radioactivity of the test sample measured by the second radioactivity detector;
track a volume of saline in the saline reservoir;
not allow the patient infusion if the volume of saline in the saline reservoir is below a predetermined saline threshold;
track a volume of waste in the waste bottle;
not allow the patient infusion if the volume of waste in the waste bottle is above a predetermined waste threshold.

US Pat. No. 10,335,536

PEN-TYPE DRUG INJECTION DEVICE HAVING MULTIPLE-USE NEEDLE MODULE WITH NEEDLE CLEANING RESERVOIR

1. A medical injection device for apportioning set doses of a liquid drug, comprisinga housing supporting a cartridge containing the liquid drug,
a needle cannula having a distal part with a distal tip and an opposite proximal part and a longitudinal lumen there between, the needle cannula being mounted relatively to the housing such that the distal part extend in a distal direction and the proximal part extend in a proximal direction and into the cartridge,
a telescopically movable shield which is telescopically movable in relation to the housing and urged in the distal direction by a spring means operable between the telescopically movable shield and the housing, and wherein the telescopically movable shield carries a first cleaning reservoir containing a liquid cleaning solvent for cleaning at least the distal tip of the needle cannula between subsequent injections,
wherein the first cleaning reservoir distally is sealed by a distal seal and proximally by a proximal seal longitudinal spaced from each other to define a volume containing the cleaning solvent and wherein the first cleaning reservoir further is provided with an opening connecting the first cleaning reservoir with a second overflow reservoir to accommodate a volume expansion of the liquid cleaning solvent contained in the first cleaning reservoir, and
wherein a predetermined amount of liquid cleaning solvent is present inside the second overflow reservoir.

US Pat. No. 10,335,535

INJECTION DEVICE WITH A NEEDLE CANNULA

1. An injection device for injecting a pharmaceutical liquid drug containing a preservative, comprising:a housing supporting a cartridge permanently embedded in the injection device, the cartridge having an interior chamber containing the pharmaceutical preservative containing liquid drug to be injected,
a needle cannula permanently secured to the injection device, and usable for multiple injections and having a front part with a tip and a back part, which back part is adapted to be in liquid communication with the interior chamber of the cartridge, and
a telescopic needle covering shield, which distally is provided with a reservoir confining a predetermined volume of a liquid for cleaning at least the tip of the needle cannula between subsequent injections, and which telescopic needle covering shield is urged distally into a first position by a first resilient member and moved proximally against the bias of the first resilient member into a second position during injection;
the first position being a position in which, the tip of the front part of the needle cannula is located inside the reservoir, and
the second position being a position in which, the tip of the front part of the needle cannula is located outside the reservoir and distally to the reservoir,and wherein, the predetermined volume of liquid confined in the reservoir of the telescopic needle covering shield is the identical same pharmaceutical preservative containing liquid drug as present in the interior chamber of the cartridge, such that the identical same pharmaceutical preservative containing liquid drug is present in both the reservoir of the telescopic needle covering shield and in the interior chamber of the cartridge, andwherein the injection device automatically ejects a predetermined amount of pharmaceutical preservative containing liquid drug into the reservoir upon first use of the injection device.

US Pat. No. 10,335,534

DIALYSIS PRESCRIPTION OPTIMIZATION FOR DECREASED ARRHYTHMIAS

Medtronic, Inc., Minneap...

1. A method, comprising:determining a potassium concentration of a patient;
determining a fluid volume of the patient;
calculating a desired potassium concentration change and a desired fluid volume change for a dialysis session, wherein the desired potassium concentration change and desired fluid volume change are calculated based on a first risk score for arrhythmia due to an anticipated change in potassium concentration and an anticipated change in fluid volume during dialysis; and
setting an ultrafiltration prescription and/or a potassium prescription based in part on the desired potassium concentration change and desired fluid volume change;
wherein the method uses a system comprising:
a dialysate flow loop comprising a dialyzer; wherein dialysate enters the dialyzer through a dialysate inlet and exits the dialyzer through a dialysate outlet;
an extracorporeal flow loop for transporting blood from the patient, to the dialyzer, and back to the patient;
an ultrafiltration pump, wherein the ultrafiltration pump controls a net fluid movement between the patient and the dialysate flow loop;
control electronics, wherein the control electronics are configured to control a pump rate of the ultrafiltration pump;
a processor; wherein the processor is configured to obtain the potassium concentration of the patient;
the processor configured to calculate the first risk score for arrhythmia, wherein the first risk score for arrhythmia is based at least in part on the potassium concentration of the patient and the fluid volume of the patient; and wherein the processor calculates the ultrafiltration prescription based on the first risk score for arrhythmia and transmits the ultrafiltration prescription to the control electronics; and
wherein the control electronics are configured to control the pump rate of the ultrafiltration pump based on the ultrafiltration prescription.

US Pat. No. 10,335,533

DEVICE FOR SEPARATING BLOOD INTO ITS COMPONENTS AS WELL AS A METHOD FOR DOING SO AND USE OF SUCH A DEVICE

FRESENIUS MEDICAL CARE DE...

1. A device for separating blood into its components, comprisinga magnetic bearing and drive device,
a container having a cylindrical shape suspended during operation in the bearing and drive device in a magnetically floating manner, having an axis, about which axis the container is rotated by the bearing and drive device during operation, and having at least one open end,
at least one tube-shaped inlet and at least one outlet provided, independently, in the at least one open end of the container,
at least one magnet connected to, or integrated into, the container, and
a control device configured to control the at least one magnet and the magnetic bearing and drive device for securing and accurately positioning the container in the bearing and drive device during operation.

US Pat. No. 10,335,532

DIALYSIS SYSTEM HAVING AUTOIDENTIFICATION MECHANISM

Baxter International Inc....

1. A dialysis system comprising:a dialysis instrument including at least one pump actuator;
a disposable cassette operable with the at least one pump actuator;
a plurality of disposable cassette supply connections;
a plurality of dialysis solution lines, each of the plurality of dialysis solution lines connected to a dialysis solution supply container and including a dialysis solution line connector;
an autoidentification mechanism configured to automatically identify information associated with each of the dialysis solution line connectors to determine each of (i) dialysis solution type, (ii) dialysis solution volume, and (iii) a number of the dialysis solution supply containers to supply the dialysis instrument for a treatment, the autoidentification mechanism further configured to automatically (a) image a geometry of each of the dialysis solution line connectors, and (b) compare the imaged geometry to a range of stored imaged geometries to determine
whether any of the dialysis solution line connectors is improperly positioned,
whether any of the dialysis solution line connectors is deformed, and
whether any of the dialysis solution line connectors is unmatched with respect to a particular therapy prescription; and
a controller configured to allow dialysis solution to be automatically drawn from the dialysis solution supply containers if the autoidentification mechanism confirms that correct dialysis solution supply containers are connected.

US Pat. No. 10,335,531

SYSTEM AND METHOD FOR CARDIOPULMONARY BYPASS USING HYPOBARIC OXYGENATION

1. A system for cardiopulmonary bypass, comprising:a cardiopulmonary bypass reservoir configured to store a blood;
a pump in fluid communication with the cardiopulmonary bypass reservoir configured to provide pressure to the system;
an oxygen source comprising a pressure regulator configured to regulate an oxygen pressure;
an oxygenator fluidly connected to the pressure regulator of the oxygen source via a sweep gas inlet, wherein the sweep gas inlet is configured to have a subatmospheric pressure and the oxygenator is configured to oxygenate the blood;
a vacuum regulator fluidly connected to the oxygenator via a sweep gas outlet, and configured to provide the subatmospheric pressure;
a vaporizer in fluid communication with the oxygenator;
a flow restrictor fluidly connected to the sweep gas inlet and configured to allow for a pressure drop from the oxygen source to the oxygenator, and disposed between the vaporizer and the oxygenator; and
an arterial filter fluidly connected to a blood outlet of the oxygenator and to the cardiopulmonary bypass reservoir.

US Pat. No. 10,335,530

LUNG ASSIST DEVICE WITH OSCILLATING FIBER BUNDLE

1. An extracorporeal system for lung assist comprising:a system housing, the system housing comprising a blood flow inlet and a blood flow outlet;
a fiber bundle housing movably positioned within the system housing, the fiber bundle housing comprising a gas inlet and a gas outlet;
a fiber bundle in operative connection with the fiber bundle housing, the fiber bundle comprising a plurality of hollow gas permeable fibers, wherein lumens of the plurality of hollow gas fibers are in fluid connection with the gas inlet at a first end thereof and in fluid connection with the gas outlet as a second end thereof;
an actuator to impart linear oscillatory motion to the fiber bundle housing and thereby to the fiber bundle.

US Pat. No. 10,335,529

EXTRA-CORPOREAL BLOOD TREATMENT DEVICE AND METHOD FOR SWITCHING OFF OR REDUCING THE SPEED OF A NON-OCCLUDING PUMP IN A FLUID SYSTEM OF AN EXTRA-CORPOREAL BLOOD DEVICE

Fresenius Medical Care De...

1. An extracorporeal blood treatment apparatus comprising:a fluid system comprising a blood feed line that leads to a blood treatment unit, and a blood discharge line that leads away from the blood treatment unit, wherein the blood treatment unit is divided into a blood chamber and a dialysis fluid chamber by means of a semi-permeable membrane,
a pump configured to (1) convey blood in the blood feed line or in the blood discharge line of the fluid system, or (2) convey dialysis fluid through the dialysis fluid chamber, wherein the pump is a non-occluding pump,
a first shut-off element for shutting off the blood feed line and a second shut-off element for shutting off the blood discharge line, and
a control unit for controlling the first shut-off element, the second shut-off element and the non-occluding pump,
wherein the control unit is configured such that before the speed of rotation of the pump is reduced or before the pump is shut off, the first shut-off element and the second shut-off element are closed, and the speed of rotation of the pump is reduced or the pump is shut off only after a predetermined time interval has lapsed, the predetermined time interval beginning after the first shut-off element and the second shut-off element are closed.

US Pat. No. 10,335,528

TRANSCATHETER METHOD AND SYSTEM FOR THE DELIVERY OF INTRACORPOREAL DEVICES

NUHEART AS, Bergen (NO)

1. A method for the transcatheter delivery of an intracorporeal device comprising:a step of establishing a device delivery pathway in a patient, wherein said device delivery pathway extends at least from an entry point into the patient to an exit point from the patient, and
a step of coupling the intracorporeal device to a delivery system, said delivery system being arranged and configured to extend, in use, at least to the entry point and to the exit point of the device delivery pathway,
wherein the delivery system comprises at least two delivery devices, each delivery device being coupled to an end of the intracorporeal device.

US Pat. No. 10,335,527

VENTRICULAR ASSIST ASSEMBLY, SYSTEM, AND METHOD

THE REGENTS OF THE UNIVER...

1. A method of attaching an implantable anastomotic assembly to cardiovascular tissue, the method comprising:engaging a connection interface against the cardiovascular tissue;
engaging an outer plate against the cardiovascular tissue a distance away from the connection interface; and
after engaging the connection interface and the outer plate against the cardiovascular tissue, interconnecting the connection interface to the outer plate using a connector;
wherein before interconnecting the connection interface and the outer plate, the connection interface is separate from and non-contiguous with the outer plate.

US Pat. No. 10,335,526

DETACHABLE PERCUTANEOUS CONNECTOR

HeartWare, Inc., Miami L...

1. A cover for a percutaneous connector extending through the skin of a patient comprising:an enclosure having an inner side and an outer side and defining a depression;
a first separable connector mounted to the enclosure and disposed entirely within the enclosure, the first separable connector being configured to detachably engage and electrically connect with the percutaneous connector, the enclosure being configured to isolate a distal end of the percutaneous connector from an exterior of the enclosure;
a second separable connector mounted to the enclosure and disposed within the depression, the second separable connector being electrically connected to the first separable connector, the second separable connector being exposed at the outer side of the enclosure and being configured to detachably engage and electrically connect with an external device, the second separable connector being spaced apart from the first connector by a cable; and
the inner side of the enclosure defining a skin-engaging surface at least partially surrounding the first separable connector and the percutaneous connector, when the first separable connector is engaged with the percutaneous connector.

US Pat. No. 10,335,525

BREASTSHIELD WITH MEDIA SEPARATION

MEDELA HOLDING AG, Baar ...

1. A breastshield unit for use in a device for expressing human breastmilk by means of underpressure applied to a nipple, wherein the device comprises an underpressure source for generating the underpressure applied to the nipple, wherein the breastshield unit comprises a breastshield body with a first opening for receiving the nipple of a mother's breast, with a second opening as a drain for expressed breastmilk and with at least one third opening for connection to the underpressure source in order to apply the underpressure to the nipple, wherein the breastshield unit further comprises a media separation membrane arranged in the breastshield body, the media separation membrane being made of a flexible material and transferring the underpressure generated by the underpressure source to the nipple and the media separation membrane separating the first opening and the second opening from the at least one third opening and therefore separating the expressed breastmilk from the underpressure source and therefore protecting the underpressure source from contamination by the expressed breastmilk, wherein the media separation membrane comprises a through-channel which connects the first opening of the breastshield body to the second opening of the breastshield body, the underpressure source disposed outside of the media separation membrane, wherein the through-channel comprises a through-opening, which is enlarged when subjected to the underpressure from the underpressure source, the through-opening being formed by walls of the media separation membrane, wherein the walls, when subjected to the underpressure, are moved away from each other in order to enlarge the through-opening from an initially closed or almost closed condition, mainly by purely geometric shifting of the position of the walls, the shifting of the position of the walls being caused by the underpressure generated by the underpressure source.

US Pat. No. 10,335,524

PORTABLE CHEST TUBE PRESSURE AND CO2 MONITOR

Mayo Foundation for Medic...

1. A chest tube thoracostomy system comprising:one or more sensors that are configured to detect a level of CO2 and a pressure of gas that is passing through a chest tube between a patient and a vacuum source; and
a monitoring device that is configured to be in electrical communication with the one or more sensors and that is configured to receive, from the one or more sensors, one or more signals that are indicative of the detected level of CO2 and the detected pressure of the gas that is passing through the chest tube between the patient and the vacuum source, the monitoring device comprising a user interface that is configured to display indications of the detected level of CO2 and the detected pressure,
wherein the monitoring device is configured to algorithmically process the one or more signals that are indicative of: (i) the detected level of CO2 and (ii) the detected pressure in combination with each other to enable determining whether the chest tube needs to be repositioned within the patient.

US Pat. No. 10,335,523

INCONTINENCE AID

1. A method of attaching an incontinence aid to a man, the method comprising:(a) positioning a pad body of the incontinence aid such that an interior side of the pad body adjacent a proximal end of the pad body is under the man's genitals;
(b) folding a first side edge of the pad body over at least a portion of the man's genitals such that the interior side of the pad body adjacent the proximal end of the pad body and adjacent the first side edge of the pad body faces at least a portion of the man's genitals;
(c) folding a second side edge of the pad body over the first side edge of the pad body such that the interior side of the pad body adjacent the proximal end of the pad body and adjacent the second side edge of the pad body faces at least a portion of an exterior side of the pad body adjacent the proximal end of the pad body and adjacent the first side edge of the pad body;
(d) folding the pad body such that the interior side of the pad body adjacent a distal end of the pad body faces at least a portion of the exterior side of the pad body to cover the man's genitals; and
(e) securing the pad body in a folded position to retain the pad body on the man's genitals.

US Pat. No. 10,335,522

INTERFACES, SYSTEMS, AND METHODS FOR USE IN REDUCED PRESSURE TISSUE TREATMENT

KCI Licensing, Inc., San...

1. A system for treating a tissue site with a reduced pressure, comprising:a manifold for placing proximate the tissue site, the manifold having a first side and a second side, the second side of the manifold adapted to face the tissue site;
a flexible film drape for covering the first side of the manifold to form a sealed space containing the manifold, the flexible film drape having an aperture adapted to provide fluid communication with the sealed space;
an interface for positioning over the flexible film drape proximate the aperture, the interface having a first side and a second side, the second side of the interface adapted to face the tissue site, the interface comprising:
an inlet port positioned proximate the first side of the interface and adapted to intake ambient gas, the inlet port comprising a constricted portion having a first diameter at an upstream end and a second diameter at an opposing downstream end, wherein the second diameter is smaller than the first diameter, and wherein the constricted portion is adapted to provide a pressure drop,
a first reduced-pressure channel extending through the interface from the inlet port to an outlet port positioned proximate the first side of the interface,
a second reduced-pressure channel adapted to deliver the reduced pressure to the tissue site, the second reduced-pressure channel fluidly coupled between the first reduced-pressure channel and the second side of the interface, wherein the reduced pressure substantially corresponds to the pressure drop, and
a pressure-sensing port positioned in the second side of the interface;
a reduced-pressure source fluidly coupled to the outlet port; and
a pressure-sensing unit fluidly coupled to the pressure-sensing port for monitoring pressure proximate the tissue site.

US Pat. No. 10,335,521

REDUCED PRESSURE THERAPY DEVICES

The Board of Trustees of ...

1. A reduced pressure therapy system, the system comprising:a wound dressing comprising:
a sealing film comprising an adhesive region, wherein the sealing film is configured to be affixed around an area of tissue to be treated and create a sealed enclosure,
an outlet port, and
a contact layer comprising a plurality of stacked sheets retained by a porous layer;
a suction apparatus configured to generate reduced pressure of at least ?50 mm Hg, the suction apparatus comprising:
a first chamber having a distal end and a proximal end, wherein the first chamber has rigid sides having first threads from the distal end to the proximal end of the first chamber on an internal surface,
a reciprocating member comprising second threads on an outer surface configured to engage the first threads to form a threaded interface allowing the reciprocating member to sealably rotate along the rigid sides,
a second chamber, and
a valve controlling fluid communication with the second chamber; and
an extension tube configured to attach to the outlet port of the wound dressing and to the suction apparatus.

US Pat. No. 10,335,520

DEVICE AND METHOD FOR CLEARING TUBING

VECTOR SURGICAL, LLC, Wa...

1. A device for moving contents of a tube by acting on an exterior of the tube comprising: a housing including a top portion and a bottom portion, the top portion including a tube passageway extending along a length thereof for holding a tube therein; a roller chassis moveable between a first position and a second position and coupled to the housing; a first roller for contacting the tube, the first roller housed within the roller chassis and moveable between a first position in which the tube is disengaged and a second position in which the tube is engaged; a second roller rotatably coupled to an actuator for rotatably energizing the second roller, the second roller moveable between a first position in which the tube is disengaged and a second position in which the tube is engaged, the first roller and the second roller configured to matingly compress the tube; biasing means for biasing the first roller and the second roller in opposite directions; and at least a first lever operably coupled to the housing, the first lever configured to actuate the actuator and move the second roller to the second position.

US Pat. No. 10,335,519

DYNAMIC SILK COATINGS FOR IMPLANTABLE DEVICES

TRUSTEES OF TUFTS COLLEGE...

1. An implantable device comprising a silk body and a reservoir,the silk body comprising an outer surface, wherein at least a portion of the outer surface comprises a silk coating;
the silk body further comprising conduits formed between the outer surface and the reservoir; and
the reservoir configured to hold a silk matrix therein, wherein the silk matrix forms the silk coating upon discharge from the reservoir onto the at least a portion of the outer surface through the conduits.

US Pat. No. 10,335,518

CATHETER LOCKING FORMULATION AND METHOD TO PREPARE SAME

1. A method to prepare a catheter locking formulation, comprising the following steps in the following order:dissolving trimethoprim in propylene glycol at a temperature between about 50° C. and about 55° C. with stirring for at least 60 minutes to form a solution of trimethoprim and propylene glycol;
sequentially adding at a temperature between about 50° C. and about 55° C., in the following order, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin, to said trimethoprim/propylene glycol solution, wherein glycerin should be added only after all solids have been completely solubilized;
cooling said propylene glycol solution containing trimethoprim, propylene glycol, phosphate buffered saline, EDTA Calcium Disodium Hydrate, and glycerin to about room temperature;
adding absolute ethanol at about room temperature to a room temperature solution of trimethoprim, propylene glycol, EDTA Calcium Disodium Hydrate, phosphate buffered saline, and glycerin to form a catheter locking solution;
wherein said absolute alcohol is present at a level of at least fifteen (15) weight percent of said catheter locking solution;
wherein said catheter locking solution maintains shelf life stability, including no formation of precipitates, at temperatures between 0° C. to about 42° C. for at least three days; and
wherein said catheter locking solution comprises a pH between about 8 and about 9.

US Pat. No. 10,335,513

HYDROPHILIZATION AND ANTIFOULING OF ENHANCED METAL SURFACES

Cardiac Pacemakers, Inc.,...

1. A method for coating a roughened titanium surface of an implantable medical device, the method comprising:providing a material with a roughened titanium metal surface;
activating at least a portion of the roughened titanium surface with an oxygen containing plasma, wherein the activating step forms hydroxyl groups on the titanium surface; and
treating the activated roughened titanium surface with a poly(ethylene glycol) to covalently bond the poly(ethylene glycol) directly to a titanium atom of the roughened titanium surface by an inorganic ether bond.

US Pat. No. 10,335,510

METHOD AND DEVICE FOR FEMALE URINARY INCONTINENCE

ParaPatch, Inc., Campbel...

1. A patch for treating female urinary incontinence, the patch sized and configured to fit directly on and cover a clitoris without covering a urethra, the patch configured when applied to stimulate the clitoris to inhibit discharge from a bladder.

US Pat. No. 10,335,508

SYSTEMS AND METHODS FOR SANITIZING SURFACES

LivOnyx Inc., Allston, M...

1. A method for killing or inactivating pathogens on a surface, comprising:spraying an aerosolized layer of an active agent onto the surface, the layer being a thin and substantially uniform coating,
wherein the spraying occurs over a first time period and the aerosolized layer dries over a second time period while being effective to kill or inactivate the pathogen on the surface, and wherein a duration of the first and second time periods together is less than 5 seconds.

US Pat. No. 10,335,507

STERILIZATION SYSTEM FOR A BLOW/FILL/SEAL MACHINE

Weiler Engineering, Inc.,...

1. A sterilization system for a blow/fill/seal machine having a fill assembly, and comprisinga shroud enclosing the fill assembly and defining a plenum, a sterilizing gas inlet and a sterilizing gas outlet;
an external conduit defining at least one sterilizing gas flow passageway between said sterilizing gas inlet and said sterilizing gas outlet;
a blower in the external conduit adjacent to said sterilizing gas inlet for introducing into and circulating the sterilizing gas through the shroud;
a sterilizing gas source connected to the external conduit upstream from the blower in confined flow communication with the blower; and
a humidifier and a humidified conduit in confined flow communication with the external conduit between the blower and a HEPA filter.

US Pat. No. 10,335,506

MOBILE ULTRAVIOLET LAMP APPARATUSES HAVING A REFLECTOR SYSTEM THAT REDIRECTS LIGHT TO A HIGH TOUCH AREA OF A ROOM

Xenex Disinfection Servic...

1. An apparatus, comprising:a germicidal lamp configured to emit ultraviolet light, wherein the germicidal lamp is arranged lengthwise substantially parallel to a horizontal plane of the apparatus;
a mobile carriage supporting the germicidal lamp, wherein the mobile carriage comprises:
one or more compartments underneath said arranged germicidal lamp, wherein the one or more compartments hold operational components for the apparatus;
a casing enclosing the one or more compartments, wherein the apparatus is configured such that the germicidal lamp is not moveable beyond vertical planes aligned with the casing when the germicidal lamp is supported by the mobile carriage; and
wheels along a bottom of the mobile carriage to affect portability of the apparatus; and
a reflector system arranged in the apparatus such that ultraviolet light emitted from the germicidal lamp is projected to a region exterior to the apparatus between approximately 2 feet and approximately 4 feet from a floor of a room in which the apparatus is arranged, wherein the apparatus is configured such that a reflector of the reflector system is moveable relative to the mobile carriage.

US Pat. No. 10,335,505

STERILIZATION DEVICE FOR INCISION AND WOUND SITES UTILIZING LOW INTENSITY UV-C RADIATION AND OZONE

Hepco Holdings, LLC, Sem...

13. A system for radiating skin comprising:an enclosure;
one or more ultraviolet emitters housed in the enclosure and covered by a filter, the filter passing ultraviolet light from the one or more ultraviolet emitters, the one or more ultraviolet emitters configured to emit ultraviolet light from the housing, through the filters, and onto a surface of skin where ozone is produced by ultra violet light emitted from the one or more ultraviolet emitters;
means for detecting contact with the surface of the skin, the means for detecting contact prevents the one or more ultraviolet emitters from emitting the ultraviolet light until contact is made with the surface of the skin; and
a timer configured to connect a source of power to the one or more ultraviolet emitters for a period of time responsive to the means for detecting the surface indicating contact with the surface of the skin;
wherein the one or more skin contact detectors comprises an ultrasonic distance measurement device that detects proximity to the skin.

US Pat. No. 10,335,504

HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS

Washington University, S...

1. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting ofor a pharmaceutically acceptable salt thereof.

US Pat. No. 10,335,503

COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR

Public University Corpora...

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof or solvate thereof:
wherein:
each of A and Z independently is CO, SO, or SO2;
each of X and Y independently is S or O;
each of R1, R3, and R4 independently is hydrogen, alkyl, alkenyl, alkynyl, or halo;
R2 is alkyl, alkenyl, or alkynyl;
each R5 independently is alkyl, alkenyl, alkynyl, or halo; and
n is an integer of 0 to 4.

US Pat. No. 10,335,497

PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF

MEDIMMUNE LIMITED, Cambr...

1. A method of synthesising compound B:
from:

via the intermediate:
which comprises the steps of:(i) removing the Alloc
protecting groups; and(ii) reacting the product of (i) with Mal-(PEG)8-acid.

US Pat. No. 10,335,496

ROR1 ANTIBODY IMMUNOCONJUGATES

VelosBio Inc., San Diego...

1. An immunoconjugate comprising an antibody conjugated to a cytotoxic drug moiety, wherein the VH and VL of the antibody comprise the amino acid sequences of SEQ ID NOs: 5 and 6, respectively, and the immunoconjugate isADC-A, having the structure












wherein Ab in the structure is the antibody.

US Pat. No. 10,335,495

BIOMOLECULE CONJUGATES

CELGENE CORPORATION, Sum...

1. A compound of Formula I
wherein
A is dibenzocyclooctynyl, cyclooct-4-ynoxyl, or (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethyloxy;
D is a maytansinoid;
m is 1;
E is

wherein:
J is an amino acid or peptide;
h is an integer from 0 to 30;
d, e, g, j, and k are each independently an integer from 1 to 30;
each R4 is independently H, alkyl, —N(R3)2, —SR3, and C1-C8 alkoxy, aryl;
each of R3 or R3? is H, C1-C8 alkyl; and
“d is 5” and “R3? is H” are not satisfied simultaneously.

US Pat. No. 10,335,491

CATALYTIC DELIVERY NANOSUBSTRATES (CDNS) FOR HIGHLY EFFICIENT DELIVERY OF BIOMOLECULES

The Regents of the Univer...

1. A molecular delivery system, comprising:a substrate having
a nanostructured surface region which comprises a plurality of nanostructures and, covalently attached to the nanostructured surface region, multiple copies of a first member of a binding pair; and
at least one vector nanoparticle which comprises
encapsulated therein, a molecule of interest, and,
on its surface, multiple copies of a second member of the binding pair,
wherein the plurality of nanostructures are nanofibers or nanowires made of silicon, titanium, aluminum, steel, or an organic oxide, or are organic polymers comprising at least one of polymethacrlate, polysaccharide or polylactide,
wherein the plurality of nanostructures comprise a length and diameter such that the length is greater than the diameter,
wherein the plurality of nanostructures are attached at a first end to the substrate, and
wherein the first member of the binding pair is covalently attached to an outer surface region of the plurality of nanostructures such that the at least one vector nanoparticle is attached to the outer surface region of the plurality of nanostructures when the second member of the binding pair and the first member of the binding pair are engaged, and
wherein each vector nanoparticle further comprises:
a plurality of structural components that are suitable to at least provide some mechanical structure to said vector nanoparticle;
a plurality of binding components, each having a plurality of binding regions adapted to bind to said plurality of structural components; and
a plurality of terminating components, each of which is adapted to bind to a binding region of one of said plurality of binding components,
wherein said plurality of structural components and said plurality of binding components self-assemble when brought into contact to form said vector nanoparticle,
wherein said plurality of terminating components act to occupy binding regions of said plurality of binding components to terminate further binding when said plurality of terminating components are present in a sufficient quantity relative to said plurality of binding regions of said plurality of binding components,
wherein the plurality of binding regions comprise ?-cyclodextrin,
wherein each of said plurality of structural components comprises at least one binding element adapted to bind to the binding regions to form a first inclusion complex,
wherein the binding element comprises adamantine,
wherein the first inclusion complex is adamantine-?-cyclodextrin,
wherein each of the plurality of terminating components comprise a single terminating binding element that binds to remaining binding regions of one of said plurality of binding components by forming a second inclusion complex,
wherein said terminating binding element comprises adamantine, and
wherein said second inclusion complex is adamantine-?-cyclodextrin.

US Pat. No. 10,335,490

FLUORINATED POLYMERIZABLE HYDROGELS FOR WOUND DRESSINGS AND METHODS OF MAKING SAME

The University of Akron, ...

1. A hydrogel comprising:crosslinked polymers, the polymers having polysaccharide backbone chains, wherein the polysaccharide backbone chains have a pendant fluorine group attached thereto; and
wherein the polysaccharide backbone chains include one or more saccharide units that include an alkene group selected from the group consisting of:

US Pat. No. 10,335,489

INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE PI OF WHICH IS BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED CO-POLYAMINO ACID

ADOCIA, Lyons (FR)

1. A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least:a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5;
b) a prandial insulin,
c) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic groups, chosen from the co-polyamino acids of formula I:

 in which:
A independently represents either a —CH2— group (aspartic unit) or a —CH2—CH2— group (glutamic unit),
R1 is a radical chosen from the group consisting of an H, a linear C2 to C10 acyl group, a branched C3 to C10 acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate,
R2 is an —NR?R? radical, R? and R?, which may be identical or different, being chosen from the group consisting of H, linear or branched or cyclic C2 to C30 alkyls and benzyl, and said R? and R? alkyls being alkyls which can together form one or more saturated, unsaturated and/or aromatic rings which are carbon-based and/or which can comprise heteroatoms, chosen from the group consisting of O, N and S,
R?3 is a radical chosen from the group consisting of the radicals of formulae —OR3, II or II?:

 in which * indicates the site of attachment to the co-polyamino acid
R3 and R?3, which may be identical or different, represent an H or a cationic entity chosen from the group comprising metal cations,
—R is a hydrophobic radical chosen from the group consisting of a saturated or unsaturated, linear or branched C8 to C30 radical which can comprise heteroatoms or a C8 to C30 radical which can form rings which are carbon-based or which can comprise heteroatoms, which are saturated, unsaturated and/or aromatic, said rings possibly being ortho-condensed or peri-condensed, or a radical of formula III or III? as defined below:

 in which * indicates the site of attachment to the co-polyamino acid, and
R4 and R?4, which may be identical or different, represent an H, a cationic entity chosen from the group comprising metal cations, an R?4 radical or an R??4 radical, and at least one of R4 and R?4 is equal to R?4,
R?4 represents a saturated or unsaturated, linear or branched C8 to C30 radical which can comprise heteroatoms or a C8 to C30 radical which can form rings which are carbon-based or which can comprise heteroatoms, which are saturated, unsaturated and/or aromatic, said rings possibly being ortho-condensed or peri-condensed,
R??4 represents a saturated or unsaturated, linear or branched C1 to C7 radical which can comprise heteroatoms or a C1 to C7 radical which can form rings which are carbon-based or which can comprise heteroatoms, which are saturated, unsaturated and/or aromatic, said rings possibly being ortho-condensed or peri-condensed, and
B independently represents either a —CH2— group (aspartic unit) or a —CH2—CH2— group (glutamic unit),
R5 is a radical chosen from the group consisting of an H, a linear or branched C1 to C4 alkyl or a benzyl group,
n/(n+m) is defined as the molar degree of grafting with hydrophobic radical of the monomeric units and is between 1 and 50 mol %,
n+m represents the degree of polymerization of the co-polyamino acid, i.e. the average number of monomeric units per chain of co-polyamino acid, and 5 ?n+m?1000.

US Pat. No. 10,335,487

METHODS FOR TARGETING OR STIMULATING CELLS OR ORGANISMS USING NANOPARTICLES AND EXTERNAL FIELD

Ping Liang, Newport Coas...

1. A method for targeting cells that are less negatively charged than surrounding cells comprisinginjecting a solution of nano-particles at an area, wherein the nano-particles are Magneto-Electric Nano-Particles (MENPs),
increasing negative charges of the nano-particles so as to produce an electric gradient field, which is accomplished by applying for a period of time an external field on the MENPs; and
the electric gradient field pushing or driving the nano-particles from the area toward the less negatively charged cells;
wherein the method further comprises (1) placing, injecting or implanting one or more permanent magnets or electro-magnets in a cancer site, wherein the magnets) serves to attract MENPs to and increase accumulation of MENPs in the cancer site, as well as to increase the negative charges of the MENPs to steer the MENPs towards cancer cells; (2) injecting or implanting wires, liquid capsules, injectable macro-particles, made of permanent magnetic material into a solid tumor site that is inside a body or an organ, wherein the magnetic field produced by these injected or implanted magnetic sources serve to localize and accumulate the MENPs at cancer sites, and at the same time to enhance the electric field gradient to push MENPs to cancer cells; or (3) using an apparatus formed into a shape and dimension to fit a target area or volume that is made of or using permanent magnetic material and with one or more electromagnets embedded in the apparatus to generate a constant magnetic field and a changing magnetic field simultaneously.

US Pat. No. 10,335,477

COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING AND TREATING SALMONELLA TYPHI AND SALMONELLA PARATYPHI INFECTION

YALE UNIVERSITY, New Hav...

1. An immunological composition comprisinga.) a mutant Pertussin-like toxin A (PltA) polypeptide comprising the mutation E133A within SEQ ID NO: 8,
b.) a mutant Cytolethal distending toxin B (CdtB) polypeptide comprising the mutation H160Q within SEQ ID NO: 7 and
c.) a Pertussin-like toxin B (PltB) polypeptide.

US Pat. No. 10,335,452

METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1

Mallinckrodt Hospital Pro...

1. A method of treating type 1 hepatorenal syndrome (HRS-1), the method comprising:identifying a plurality of patients as having HRS-1;
determining that a first patient of the plurality exhibits at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
(i) a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3,
(ii) a heart rate of greater than 90 beats per minute (BPM), and
(iii) either a partial pressure of carbon dioxide in the blood (PaCO2)<32 mmHg or a blood bicarbonate (HCO3) level<23 mmol/L;
determining that the first patient does not have overt sepsis, septic shock, or uncontrolled infection;
determining that, because the first patient exhibits at least two of the three criteria and does not have overt sepsis, septic shock, or uncontrolled infection, the HRS-1 of the first patient is likely to respond to treatment with terlipressin;
administering to the first patient an amount of terlipressin effective to treat HRS-1 in the first patient;
determining that a second patient of the plurality exhibits only one or none of the three criteria or has overt sepsis, septic shock, or uncontrolled infection;
determining that, because the second patient does not exhibit at least two of the three criteria or has overt sepsis, septic shock, or uncontrolled infection, the HRS-1 of the second patient is unlikely to respond to treatment with terlipressin;
excluding the second patient from treatment with terlipressin determining that a third patient of the plurality has overt sepsis, septic shock, or uncontrolled infection; and
excluding the third patient from treatment with terlipressin.

US Pat. No. 10,335,445

COMPOSITIONS AND METHODS OF ANTIALLERGIC PHORBOL ESTER AND PHORBOL DERIVATIVES AS THE MAIN ACTIVE INGREDIENTS FROM THE SEEDS OF AQUILARIA MALACCENSIS

WE-WIN APPLIED BIO-TECH C...

1. A method for preparing compositions from Aquilaria malaccensis seeds, the method including the following steps:(a) extracting Aquilaria malaccensis seeds that are air dried and powdered with 90% ethanol at room temperature in triplicate and concentrating the extract under a reduced pressure to provide an ethanolic extract;
(b) partitioning the ethanolic extract by suspending the ethanolic extract in water, followed by partitioning carried out with equivalent ethyl acetate in triplicate, so as to separate an organic ethyl acetate layer;
(c) subjecting the ethyl acetate layer to partitioning with n-hexane and 90% aqueous methanol (MeOH) to obtain a hexane layer and a MeOH layer;
(d) subjecting the MeOH layer to column chromatography over silica gel under gradient elution of n-hexane/CH2Cl2/MeOH of 6:3:1, 6:4:1, 6:6:1, 6:8:1, 6:10:1 and 5:10:2 to yield six respective fractions of AM1, 6:3:1; AM2, 6:4:1; AM3, 6:6:1; AM4, 6:8:1; AM5, 6:10:1; and AM6, 6:10:2;
(e) fractioning fraction AM4 over a dextran bead sizing column with a ratio of CH2Cl2/MeOH being 1:1 to obtain eight sub-fractions, which are respectively AM4-1 to AM4-8;
(f) subjecting fraction AM4-3 to column chromatography over silica under gradient elution of EtOAc/n-hexane from 1:10 to, 4:1 to obtain fifteen AM4-3 originating subfractions, which are respectively AM4-3-1 to AM4-3-15; and
(g) separating fraction AM4-4 with column chromatography on silica gel under gradient elution of EtOAc/n-hexane from 1:15 to 4:1 to obtain twelve AM4-4 originating subfractions, which are respectively AM4-4-1 to AM4-4-12,
wherein the fifteen AM4-3 originating subfractions and the twelve AM4-4 originating subfractions are further separated on column chromatography over silica gel to provide phorbol esters of the following formulas:
Formula I: 12-O-(2Z,4E,6E)-tetradeca-2,4,6-trienoylphorbol-13-acetate having a molecular formula C36H50O8 of structural formula:

Formula II: 12-deoxy-13-O-acetoylphorbol-20-octadec-9-enoate having a molecular formula C40H62O7 of structural formula:

Formula III: 12-O-(2E,4E)-6-oxohexa-2,4-dienoylphorbol-13-acetate having a molecular formula C28H34O9 of structural formula:
andFormula IV: 12-O-(2E,4E)-6,7-dihydroxytetradeca-2,4-dienoylphorbol-13-acetate having a molecular formula C36H52O10 of structural formula:
wherein Formula I derives from the subfraction AM4-4-9, Formula II derives from the subfractions AM4-3-6 and AM4-4-3, and Formulas III and IV derive from the subfraction AM4-3-13.

US Pat. No. 10,335,432

MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA

ZS PHARMA, INC., Coppell...

1. A method of treating hyperkalemia in a subject in need thereof comprising administering between 3 and 9 g per day of particles with a uniform microporous structure, a pore diameter of about 3 angstroms, and a median particle size greater than 3 microns, the particles being capable of binding potassium with a potassium exchange capacity (KEC) of at least 1.7 mEq/g, wherein less than 7% of the administered particles are under 3 microns.

US Pat. No. 10,335,431

METHOD FOR PRODUCING POLYGUANIDINES

Sealife Pharma GmbH, Tul...

1. A method for preparing polycondensation products from guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl or allyl derivatives BA according to the following reaction scheme:
wherein
each X independently represents a leaving group;
each R1 independently represents either an aromatic ring system with at least one aromatic ring, optionally containing one or more hetero atoms selected from the group consisting of O, N and S and optionally being substituted with one or two vinyl groups to which the —CH2—X group(s) is/are bound, or represents ethylene;
Gua represents a guanidindiyl, aminoguanidindiyl or diaminoguanidindiyl residue;
Y represents H-Gua, and
Z represents H; or
Y and Z together represent a chemical bond to obtain a cyclic structure; and
n is ?2;
wherein at least one benzyl or allyl derivative BA is subjected to a polycondensation reaction with excessive guanidine, aminoguanidine or diaminoguanidine G upon elimination of HX in order to provide a polyguanidine corresponding to the following formula (I), (II) or (III):

or having a cyclic structure resulting from cyclization upon elimination of a corresponding guanidine, or a salt of said polyguanidine.

US Pat. No. 10,335,426

N-ACETYL MANNOSAMMINE AS A THERAPEUTIC AGENT

THE UNITED STATES OF AMER...

1. A method of treating a condition or disease in a mammal in need thereof comprising selecting a subject with the condition or disease, and administering to the subject an effective amount of N-acetyl mannosamine or a derivative thereof, to the mammal, wherein the derivative consists of Formula I.wherein R1, R3, R4, or R5 is hydrogen, lower alkanoyl, carboxylate or lower alkyl; R2 is lower alkyl, lower alkanoylalkyl, lower alkyl alkanoyloxy; and the condition or disease is diabetic nephropathy.

US Pat. No. 10,335,425

COMPOSITIONS AND METHODS OF TREATING OF BACTERIAL INFECTIONS WITH ?-LACTAMASE INHIBITORS

CASE WESTERN RESERVE UNIV...

1. A pharmaceutical composition comprising a therapeutically effective amounts of at least one ?-lactam antibiotic and at least one triazolylmethyl boronic acid, wherein the triazolylmethyl boronic acid is selected from the group consisting of:
wherein R1?CH2NHC(?O)-phenyl or benzyl, CH2NHS(?O)2-phenyl or alkyl substituted phenyl, —COOH, ester, aryl, heteroaryl, or —CH2Oaryl;
R3=benzyl, alkyl, H or —CH2-benzoic acid;
R4±S(?O)2-phenyl or alkyl substituted phenyl, C(?O)-phenyl or benzyl, C(?O)NH-phenyl;
R5=—COOH or H; and pharmaceutically acceptable salts thereof.

US Pat. No. 10,335,423

INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYLAXIS

THE UNITED STATES OF AMER...

1. A process of protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus comprising:(a) selecting a primate host not infected with the immunodeficiency retrovirus, and
(b) administering directly to the primate host a combination comprising:
i. a pharmaceutically effective amount of emtricitabine; and
ii. a pharmaceutically effective amount of tenofovir or a tenofovir prodrug,
wherein the combination is administered orally prior to the exposure of the primate host to the immunodeficiency retrovirus,
thereby protecting the primate host from infection with the immunodeficiency retrovirus.

US Pat. No. 10,335,420

NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY

The Scripps Research Inst...

1. An aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles; the liposome nanoparticles comprising a legumain-targeting lipid component and a polyethylene glycol-conjugated lipid component; the legumain-targeting lipid component comprising a hydrophobic lipid portion covalently attached to a legumain-binding moiety, wherein the legumain-targeting lipid component comprises a compound of the Formula:

US Pat. No. 10,335,419

SLOW RELEASE OXYSTEROLS AND METHODS OF USE

Warsaw Orthopedic, Inc, ...

1. A method of treating a bone defect site, the method comprising: implanting an implant at the bone defect site, the implant comprising a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol comprising (3S,5S,6S,8R,9S,10R,13S,14S,17S)17-((S)-2-hydroxyoctan-2-yl)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol (Oxy133) monohydrate encapsulated in a biodegradable polymer to control the release of the oxysterol, wherein the biodegradable polymer is in the form of microspheres disposed within a biodegradable matrix, the oxysterol is in an amount of about 5 wt % of the biodegradable matrix, the biodegradable matrix further comprising mineral particles in an amount of about 80 wt % of the biodegradable matrix, and the mineral particles comprise tricalcium phosphate and hydroxyapatite in a ratio of about 85:15, wherein the composition comprises carboxymethyl cellulose (CMC) in an amount of about 4 wt % of the composition, and the biodegradable matrix comprises collagen in an amount of about 12 wt % of the biodegradable matrix, wherein the collagen comprises insoluble and soluble collagen in a weight ratio of about 75:25 to about 65:35.

US Pat. No. 10,335,418

METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME

Topokine Therapeutics, In...

1. A method for reducing body fat in an individual, the method comprising administering systemically to the skin of the individual a pharmaceutical composition comprising a compound of formula:
or a pharmaceutically acceptable salt thereof,
wherein the individual suffers from an excess of body fat.

US Pat. No. 10,335,417

THIAZIDEAMIDE DERIVATIVE AND USE THEREOF

Institute of Pharmacology...

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from:

US Pat. No. 10,335,415

(ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES

MEI PHARMA, INC., San Di...

1. A compound of Formula II:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate or hydrate thereof; wherein:X, Y, and Z are each independently N;R1 and R2 are each independently (a) hydrogen, cyano, halo, or nitro;(b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(?NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(?NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2R1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c, or —S(O)2NR1bR1c; wherein each R1a, R1b, R1c, and R1d is independently (i) hydrogen;
(ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R1b and R1c together with the N atom to which they are attached form heterocyclyl;R3 and R4 are each independently hydrogen or C1-6 alkyl; or R3 and R4 are linked together to form a bond, C1-6 alkylene, C1-6 heteroalkylene, C2-6 alkenylene, orC2-6 heteroalkenylene;R5a is hydrogen or C1-6 alkyl;R5b is C1-6 alkyl or —C(O)OR1a;R5c is —(CR5fR5g)n—(C6-14 aryl);R5f and R5g are each independently (a) hydrogen or halo; (b) C1-6 alkyl,C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c, —OR1a, —OC(O)R1a, —OC(O)OR1a, —OC(O)NR1bR1c, —OC(?NR1a)NR1bR1c, —OS(O)R1a, —OS(O)2R1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aC(?NR1d)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d, —NR1aS(O)NR1bR1c, —NR1aS(O)2NR1bR1c, —SR1a, —S(O)R1a, —S(O)2R1a, —S(O)NR1bR1c; or —S(O)2NR1bR1c; or (d) when one occurrence of R5f and one occurrence of R5g are attached to the same carbon atom, the R5f and R5g together with the carbon atom to which they are attached form a C3-10 cycloalkyl or heterocyclyl;R6 is C1-6 alkyl; andn is 0 or 1;wherein each alkyl, alkylene, heteroalkylene, alkenyl, alkenylene, heteroalkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl in R1, R2, R3, R4, R6, R1a, R1b, R1c, R1d, R5a, R5b, R5c, R5f, and R5g is optionally substituted with one, two, three, four, or five substituents Q, wherein each substituent Q is independently selected from (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; and (c) —C(O)Ra, —C(O)ORa,—C(O)NRbRc, —C(NRa)NRbRc, —ORa, —OC(O)Ra, —OC(O)ORa, —OC(O)NRbRc, —OC(?NRbRc, —OS(O)Ra, —OS(O)2Ra, —OS(O)NRbRc, —OS(O)2NRbRc, —NRbRc, —NRaC(O)Rd, —NRaC(O)ORd, —NRaC(O)NRbRc, —NRaC(?NRd)NRbRc, —NRaS(O)Rd, —NRaS(O)2Rd, —NRaS(O)NRbRc, —NRaS(O)2NRbRc, —SRa, —S(O)Ra, —S(O)2Ra, —S(O)NRbRc, and —S(O)2NRbRc, wherein each Ra, Rb, Rc, and Rd is independently (i) hydrogen;
(ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl, each of which is further optionally substituted with one, two, three, or four substituents Qa; or (iii) Rb and Rc together with the N atom to which they are attached form heterocyclyl, which is further optionally substituted with one, two, three, or four substituents Qa; andwherein each Qa is independently selected from the group consisting of (a) oxo, cyano, halo, and nitro; (b) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) —C(O)Re, —C(O)ORe, —C(O)NRfRg, —C(NRe)NRfRg, —ORe, —OC(O)Re, —OC(O)ORe, —OC(O)NRfRg, —OC(?NRe)NRfRg, —OS(O)Re, —OS(O)2Re, —OS(O)NRfRg, —OS(O)2NRfRg, —NRfRg, —NReC(O)Rh, —NReC(O)ORh, —NReC(O)NRfRg, —NReC(?NRh)NRfRg, —NReS(O)Rh, —NReS(O)2Rh, —NReS(O)NRfRg, —NReS(O)2NRfRg, —SRe, —S(O)Re, —S(O)2Re, —S(O)NRfRg, and —S(O)2NRfRg; wherein each Re, Rf, Rg, and Rh is independently (i) hydrogen; (ii) C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) Rf and Rg together with the N atom to which they are attached form heterocyclyl.

US Pat. No. 10,335,413

SUBSTITUTED XANTHINE DERIVATIVES

Concert Pharmaceuticals, ...

1. A method of treating a disease or condition in a patient in need thereof, comprising administering to the patient an effective amount of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein R1 is selected from —CH3 and —CD3;
R2 is selected from —CH3 and —CD3; Y1 is deuterium or hydrogen, wherein the isotopic enrichment factor for each designated deuterium atom is at least 5000, wherein the disease is selected from insulin dependent diabetes, non-insulin dependent diabetes, metabolic syndrome, obesity, insulin resistance, dyslipidemia, pathological glucose tolerance, hypertension, hyperlipidemia, hyperuricemia, gout, and hypercoagulability.

US Pat. No. 10,335,410

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Millennium Pharmaceutical...

1. A method of treating lung cancer, ovarian cancer, colon cancer, breast cancer, or lymphoma in a subject, comprising administering to a subject having lung cancer, ovarian cancer, colon cancer, breast cancer, or lymphoma a therapeutically effective amount of a chemical entity which is a compound or pharmaceutically acceptable salt of formula (I):
wherein:
stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry;
Y is —O—, —CH2—, or —N(H)—;
Ra is hydrogen, fluoro, —NH2, or hydroxyl;
Ra? is hydrogen or fluoro, provided that when Ra is —NH2 or hydroxyl, Ra? is hydrogen;
Rb is hydrogen or, together with the oxygen to which it is attached, forms a prodrug;
Rc is hydrogen or C1-4 alkyl;
Rd is hydrogen, halogen, —CF3, or C1-4 alkyl;
X1 is N;
X2 is S or O;
X3 is C(Rx3) or N;
Rx3 is hydrogen, methyl, or halogen;
Z1 is hydrogen, halogen, cyano, Rz3, —S—Rz3, —S(O)—Rz3, or —S(O)2—Rz3;
Rz3 is an optionally substituted phenyl, an optionally substituted 5- to 7-membered cycloaliphatic, an optionally substituted 5- to 7-membered heterocyclyl, or an optionally substituted C1-4 aliphatic;
wherein Z1 is not hydrogen, halogen, methyl, or cyano if Z2 is hydrogen or methyl; and
(a) Z2 is a ring system having an optionally substituted 5- to 7-membered heterocyclyl with 1-2 heteroatoms or an optionally substituted 5- to 7-membered cycloaliphatic fused to
(i) an optionally substituted 5-membered heteroaryl or an optionally substituted 6-membered aryl or heteroaryl to form a bicyclic group; or
(ii) an optionally substituted 9-membered heteroaryl or an optionally substituted 10-membered aryl or heteroaryl to form a tricyclic group;
or
(b) Z2 is L-Re wherein L is L1-, —V1-L2-, or L1-V1-L2-;
L1 is a C1-3 alkylene chain wherein 1 or 2 saturated carbon atoms are optionally substituted by (Rf)(Rf?) and in which there are optionally one or two degrees of unsaturation;
each Rf is independently hydrogen; hydroxyl; —N(Rh)(Rh?); C1-4 aliphatic optionally substituted with hydroxyl, —OCH3, or cyclopropyl; —O—C1-4 aliphatic optionally substituted with hydroxyl, —OCH3, or cyclopropyl; or, together with Rf? and the carbon atom to which they are attached, form C?CH2, or a 3- to 6-membered carbocycle or 4- to 6-membered heterocycle comprising a heteroatom chosen from N (which may be protonated or C1-4 alkylated), O, or S, the heteroatom optionally located immediately adjacent to the quaternary carbon of the heterocycle;
each Rf? is independently hydrogen; C1-4 aliphatic optionally substituted with hydroxyl, —OCH3, or cyclopropyl; —O—C1-4 aliphatic optionally substituted with hydroxyl, —OCH3, or cyclopropyl; or, together with Rf and the carbon atom to which they are attached, form C?CH2, or a 3- to 6-membered carbocycle or 4- to 6-membered heterocycle comprising a heteroatom chosen from N (which may be protonated or C1-4 alkylated), O, or S, the heteroatom optionally located immediately adjacent to the quaternary carbon of the heterocycle; wherein if Rf is hydroxyl, Rf? is not —O—C1-4 aliphatic optionally substituted with hydroxyl, —OCH3, or cyclopropyl;
Rh and Rh? are each independently hydrogen or C1-4 alkyl;
V1 is —S—, —O—, —S(O)—, —S(O)2—, —C(O)— or —N(Rg)—;
L2 is a C0-2 alkylene chain wherein one saturated carbon atom is optionally substituted by (Rf)(Rf?);
Rg is hydrogen or C1-4 alkyl; and
either (i) Re is hydrogen, hydroxyl, halogen, —CF3, or an optionally substituted C1-4 aliphatic,
with the proviso that Re is not hydrogen if Rf and Rf? are present and form a ring; or
(ii) Re is a ring chosen from optionally substituted 6-membered aryl, optionally substituted 5-to 6-membered heteroaryl, optionally substituted 3- to 7-membered cycloaliphatic, or optionally substituted 4- to 7-membered heterocyclyl, which is optionally fused to a second optionally substituted 6-membered aryl, optionally substituted 5-to 6-membered heteroaryl, optionally substituted 3- to 7-membered cycloaliphatic, or optionally substituted 4- to 7-membered heterocyclyl;
or
(c) Z2 is hydrogen.

US Pat. No. 10,335,409

INHIBITORS OF HEPATITIS C VIRUS

Gilead Pharmasset LLC, F...

1. A compound of formula:

US Pat. No. 10,335,406

OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE

Elysium Therapeutics, Inc...

1. A composition comprising a macromolecule of Formula (I):
and a therapeutically-effective amount of a macromolecule of Formula (II):

or pharmaceutically acceptable salts thereof, wherein:
PD is a gastrointestinal enzyme-labile opioid agonist prodrug and the gastrointestinal enzyme-labile opioid agonist prodrug is:

wherein:
Y is H or OH;
AA is a natural or unnatural amino acid side chain that is recognized by the gastrointestinal enzyme; and
R is independently hydrogen, methyl, ethyl, substituted alkyl, acyl, a natural or unnatural amino acid, or a polypeptide comprising up to 10 natural and/or unnatural amino acids;
I is a gastrointestinal enzyme inhibitor and the gastrointestinal enzyme inhibitor is:

X2 is independently at each occurrence absent or
that joins I to a polymer P2 wherein: k and m are independently at each occurrence an integer from 0 to 10;X1 is independently at each occurrence absent or an ether, an ester, a thioester, an amide, an amine, a carbamate, a carbonate, a thioether, or a urea, wherein the nitrogen atom of the amide, amine, or carbamate, is substituted or unsubstituted and the nitrogen atoms of the urea are each independently substituted or unsubstituted, that joins PD to a polymer P1;
each P1 and P2 is independently a polyalkylene glycol; and
n is independently an integer from 1 to 2.

US Pat. No. 10,335,403

NIACIN FORMULATION

ZEENAR ENTERPRISE PTY LTD...

1. A method for prolonging the release of niacin in a subject, comprising:administering to the oral mucosa of a subject in need thereof a composition comprising an amphiphilic compound capable of self-assembling into a liquid crystalline phase upon contact with a hydrophilic solvent and a therapeutically effective amount of a niacin compound, and
prolonging release of the niacin compound in the subject for up to 12 hours.

US Pat. No. 10,335,401

NON-AROMATIC HETEROCYCLIC DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY

1. A compound represented by Formula (I):whereinX is C(?O), C(?S), or SO2;
Z is C(?O), C(?S), C(?N—RN), or SO2;
L is a single bond, —O—, —S—, or —NRN—;
R is R6 or a group represented by the following formula:

A is aromatic carbocycle, non-aromatic carbocycle, aromatic heterocycle, or non-aromatic heterocycle;
B is aromatic carbocycle, non-aromatic carbocycle, aromatic heterocycle, or non-aromatic heterocycle;
R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, substituted or unsubstituted non-aromatic heterocyclylcarbonyl, substituted or unsubstituted aromatic carbocyclyloxycarbonyl, substituted or unsubstituted non-aromatic carbocyclyloxycarbonyl, substituted or unsubstituted aromatic heterocyclyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, or substituted or unsubstituted non-aromatic heterocyclylsulfonyl;
R3 is hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, or substituted or unsubstituted non-aromatic heterocyclylsulfonyl;
R4a and R4b are each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted non-aromatic carbocycle, or substituted or unsubstituted non-aromatic heterocycle,
or, optionally, R4a and R4b are taken together with the adjacent carbon atom to form substituted or unsubstituted non-aromatic carbocycle or substituted or unsubstituted non-aromatic heterocycle;
R5 is each independently halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkynylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkynylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyloxy, substituted or unsubstituted non-aromatic carbocyclyloxy, substituted or unsubstituted aromatic heterocyclyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aromatic carbocyclylcarbonyloxy, substituted or unsubstituted non-aromatic carbocyclylcarbonyloxy, substituted or unsubstituted aromatic heterocyclylcarbonyloxy, substituted or unsubstituted non-aromatic heterocyclylcarbonyloxy, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, substituted or unsubstituted non-aromatic heterocyclylcarbonyl, substituted or unsubstituted aromatic carbocyclyloxycarbonyl, substituted or unsubstituted non-aromatic carbocyclyloxycarbonyl, substituted or unsubstituted aromatic heterocyclyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aromatic carbocyclylsulfanyl, substituted or unsubstituted non-aromatic carbocyclylsulfanyl, substituted or unsubstituted aromatic heterocyclylsulfanyl, substituted or unsubstituted non-aromatic heterocyclylsulfanyl, substituted or unsubstituted aromatic carbocyclylsulfinyl, substituted or unsubstituted non-aromatic carbocyclylsulfinyl, substituted or unsubstituted aromatic heterocyclylsulfinyl, substituted or unsubstituted non-aromatic heterocyclylsulfinyl, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, substituted or unsubstituted non-aromatic heterocyclylsulfonyl, a group represented by the formula: -L1-N?S(?O)(—RS1)—RS2, a group represented by the formula: -L1-S(?O)(?N—RN)—RS1, a group represented by the formula: —N?S(?N—RN)(—RS1)—RS2, or a group represented by the formula: —S(?N—RN)2—RS1;
R6 is each independently halogen, hydroxy, cyano, carboxy, substituted or unsubstituted carbamoyl, substituted or unsubstituted thiocarbamoyl, substituted or unsubstituted amidino, substituted or unsubstituted amino, substituted or unsubstituted ureido, substituted or unsubstituted guanidino, pentafluorothio, sulfo, substituted or unsubstituted sulfamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylcarbonyloxy, substituted or unsubstituted alkenylcarbonyloxy, substituted or unsubstituted alkynylcarbonyloxy, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfanyl, substituted or unsubstituted alkenylsulfanyl, substituted or unsubstituted alkynylsulfanyl, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkenylsulfinyl, substituted or unsubstituted alkynylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyloxy, substituted or unsubstituted non-aromatic carbocyclyloxy, substituted or unsubstituted aromatic heterocyclyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aromatic carbocyclylcarbonyloxy, substituted or unsubstituted non-aromatic carbocyclylcarbonyloxy, substituted or unsubstituted aromatic heterocyclylcarbonyloxy, substituted or unsubstituted non-aromatic heterocyclylcarbonyloxy, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, substituted or unsubstituted non-aromatic heterocyclylcarbonyl, substituted or unsubstituted aromatic carbocyclyloxycarbonyl, substituted or unsubstituted non-aromatic carbocyclyloxycarbonyl, substituted or unsubstituted aromatic heterocyclyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aromatic carbocyclylsulfanyl, substituted or unsubstituted non-aromatic carbocyclylsulfanyl, substituted or unsubstituted aromatic heterocyclylsulfanyl, substituted or unsubstituted non-aromatic heterocyclylsulfanyl, substituted or unsubstituted aromatic carbocyclylsulfinyl, substituted or unsubstituted non-aromatic carbocyclylsulfinyl, substituted or unsubstituted aromatic heterocyclylsulfinyl, substituted or unsubstituted non-aromatic heterocyclylsulfinyl, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, substituted or unsubstituted non-aromatic heterocyclylsulfonyl, a group represented by the formula: -L1-N?S(?O)(—RS1)—RS2, a group represented by the formula: -L1-S(?O)(?N—RN)—RS1, a group represented by the formula: —N?S(?N—RN)(—RS1)—RS2, or a group represented by the formula: —S(?N—RN)2—RS1;
R7a is each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyloxy, substituted or unsubstituted non-aromatic carbocyclyloxy, substituted or unsubstituted aromatic heterocyclyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, or substituted or unsubstituted non-aromatic heterocyclylsulfonyl, and
R7b is each independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyloxy, substituted or unsubstituted non-aromatic carbocyclyloxy, substituted or unsubstituted aromatic heterocyclyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, or substituted or unsubstituted non-aromatic heterocyclylsulfonyl,
or, optionally, R7a and R7b attached to the same carbon atom are taken together with the adjacent carbon atom to form substituted or unsubstituted non-aromatic carbocycle or substituted or unsubstituted non-aromatic heterocycle;
R8 is hydrogen or substituted or unsubstituted alkyl;
R9 is hydrogen, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, substituted or unsubstituted non-aromatic heterocyclylcarbonyl, substituted or unsubstituted aromatic carbocyclyloxycarbonyl, substituted or unsubstituted non-aromatic carbocyclyloxycarbonyl, substituted or unsubstituted aromatic heterocyclyloxycarbonyl, substituted or unsubstituted non-aromatic heterocyclyloxycarbonyl, substituted or unsubstituted aromatic carbocyclylsulfonyl, substituted or unsubstituted non-aromatic carbocyclylsulfonyl, substituted or unsubstituted aromatic heterocyclylsulfonyl, or substituted or unsubstituted non-aromatic heterocyclylsulfonyl;
L1 is each independently a single bond, alkylene, or C(?O);
RS1 and RS2 are each independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl, or, optionally, RS1 and RS2 bonding to the same sulfur atom are taken together with the sulfur atom to form substituted or unsubstituted non-aromatic heterocycle;
RN is each independently hydrogen, cyano, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclylcarbonyl, substituted or unsubstituted non-aromatic carbocyclylcarbonyl, substituted or unsubstituted aromatic heterocyclylcarbonyl, or substituted or unsubstituted non-aromatic heterocyclylcarbonyl;
m is an integer of 0 to 5;
n is an integer of 0 to 5; and
p is an integer of 1 to 6,or its pharmaceutically acceptable salt.

US Pat. No. 10,335,400

TREATMENT OF TAUOPATHIES WITH MGLUR5 ANTAGONISTS

The Research Foundation f...

1. A method of treating Parkinsonism-dementia complex of Guam, comprising the step of administering a pharmaceutically effective amount of an mGluR5 antagonist to a subject in need thereof to minimize a tau hyperphosphorylation in a brain thereof, wherein the mGluR5 antagonist is 2-methyl-6-(phenylethynyl) pyridine.

US Pat. No. 10,335,399

CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS MGLUR2—NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE

1. A compound having the structure:

US Pat. No. 10,335,396

METHODS OF REVERSING AUTONOMIC NERVOUS SYSTEM DAMAGE

1. A method for reducing parasympathetic excess (PE) in a subject in need thereof, comprising:administering to said subject rifaximin, wherein rifaximin is administered for 10-14 days; a polyunsaturated omega-3 fatty acid, wherein the polyunsaturated omega-3 fatty acid comprises DHA in a daily concentration range selected from: about 2,000-4,000 mg, or about 3,000 mg; and olive oil, wherein the olive oil is administered daily in an amount selected from: about 5 ml to about 100 ml, about 10 ml to about 75 ml, about 15 ml to about 50 ml, about 20 ml to about 40 ml, or about 25 ml;
providing VNS (vagal nerve stimulation) to the subject, wherein the VNS is provided transcutaneously using electrical stimulation, wherein the electrical stimulation is achieved by clipping electrodes across the tragus of an ear and inducing an electrical current with a transcutaneous electrical nerve stimulation (TENS) unit; and
placing said subject on an intermittent fasting regimen, wherein the intermittent fasting regimen comprises fasting for multiple days but not on consecutive days; and
wherein the prevalence of parasympathetic excess (PE) is decreased.

US Pat. No. 10,335,394

PROCESSES FOR PREPARING DOLUTEGRAVIR AND CABOTEGRAVIR AND ANALOGUES THEREOF

Lek Pharmaceuticals d.d.,...

1. A process for preparing a compound of formula (I) or a salt thereof
wherein
A represents CH2 or CH2—CH2,
R represents H, C1-C4 alkyl or unsubstituted or substituted phenyl,
X represents O, S, or N—R5, wherein R5 is H or C1-C4 alkyl,
Z represents hydroxy, C1-C4 alkoxy, phenoxy, benzoxy, —NH—Ar or—NH—CH2—Ar,
wherein Ar represents unsubstituted or substituted phenyl, and
* represents a chirality center, which is of (R) or (S) configuration,
the process comprising the steps of
(a) providing a compound of formula (II) or a salt thereof,

wherein A, R, X, Z, and * have the same meaning as above and
Y represents Cl or O—Ra,
wherein Ra represents C1-C4 alkyl or benzyl,
and
(b) carrying out a chemical transformation to obtain the compound of formula (I) and/or a salt thereof,
wherein the transformation is carried out in the presence of a hydroxide and methanol and/or ethanol.

US Pat. No. 10,335,393

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

Biogen MA Inc., Cambridg...

1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from hydrogen and C1-C4 alkyl;
R2 is selected from O; and
R3 is —C1-C6 alkyl, wherein R3 is optionally and independently substituted with one or more substituents selected from the group consisting of —OH, —SH, nitro, halogen, amino, cyano, C1-C12 alkyl, C2-C12 alkenyl or C2-C12 alkynyl group, C1-C12 alkoxy, C1-C12 haloalkyl, C1-C12 haloalkoxy and C1-C12 alkyl sulfanyl.

US Pat. No. 10,335,392

CYCLIC COMPOUNDS USEFUL AS MODULATORS OF TNF ?

Bristol-Myers Squibb Comp...

1. A compound of Formula (I)
or a salt thereof, wherein:
Ring A is 3- to 5-membered carbocyclic ring or 3- to 6-membered heterocyclic ring;
X is CR1 or N;
Y is —(CR5R5)m—;
Z is —(CR5R5)n—;
m is zero, 1 or 2;
n is zero, 1 or 2; provided that m+n is zero, 1, or 2;
R1 is H, halo, —CN, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy;
R2 is H, R1a, C1-6 haloalkyl, C2-6 alkenyl substituted with zero to 6 R1a, C2-6 alkynyl substituted with zero to 4 R1a, —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 7-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(mono- or bicyclic heteroaryl substituted with zero to 3 R1a);
R3 is H, halo, —CN, —CF3, —OCF3, —NO2, C1-6 alkyl substituted with zero to 6 R1a, —(CRgRg)rORe, —(CRgRg)rNRcRc, —(CRgRg)rS(O)pRb, —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 7-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(monocyclic or bicyclic heteroaryl substituted with zero to 3 R1a);
R4 is H, halo, —CN, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy;
each R5 is independently H, halo, —CN, C1-6 alkyl substituted with zero to 6 Rh, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, —(CRgRg)rC(O)Rb, —(CRgRg)rC(O)ORb, —(CRgRg)rC(O)NRcRc, —(CRgRg)rORe, —(CRgRg)rOC(O)Rb, —(CRgRg)rOC(O)NRcRc, —(CRgRg)rOC(O)ORd, —(CRgRg)rNRcRc, —(CRgRg)rNRbC(O)Rd, —(CRgRg)rNRbC(O)ORd, —(CRgRg)rNRbC(O)NRcRc, —(CRgRg)rNRbS(O)pRd, —(CRgRg)rS(O)pRb, —(CRgRg)rS(O)pNRcRc, —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 7-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(mono- or bicyclic heteroaryl substituted with zero to 3 R1a); or two R5 along with the carbon atom to which they are attached form C?O, C?NORb, or 3- to 6-membered spirocarbocyclic or spiroheterocyclic ring substituted with zero to 3 Ri;
R6 and R8 are independently H, halo, —OH, —CN, C1-5 alkyl, C1-5 hydroxyalkyl, C1-5 haloalkyl, C1-5 alkoxy, —NRxRx, —OC(O)NRxRx, —NRxC(O)ORy, —NRxC(O)Ry, —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 10-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(mono- or bicyclic heteroaryl substituted with zero to 3 R1a);
each R7 is independently halo, —OH, —CN, C1-5 alkyl, C1-5 hydroxyalkyl, C1-5 haloalkyl, —NRxRx, C1-5 alkoxy, —OC(O)NRxRx, —NRxC(O)ORy, —NRxC(O)Ry, —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 10-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(mono- or bicyclic heteroaryl substituted with zero to 3 R1a);
R9 is —(CRgRg)r(3- to 14-membered carbocyclyl substituted with zero to 3 R1a), —(CRgRg)r(aryl substituted with zero to 3 R1a), —(CRgRg)r(5- to 10-membered heterocyclyl substituted with zero to 3 R1a), or —(CRgRg)r(mono- or bicyclic heteroaryl substituted with zero to 3 R1a);
R10 is H, C1-6 alkyl, or C1-6 haloalkyl;
or R9 and R10 together with the carbon atom to which they are attached form a 5- to 6-membered spirocarbocyclic or spiroheterocyclic ring, substituted with zero to 6 Ri;
each R1a is independently F, Cl, Br, —CN, C1-6 alkyl substituted with zero to 6 Ra, C3-6 cycloalkyl substituted with zero to 6 Ra, C1-3 alkoxy substituted with zero to 6 Ra, C1-3 haloalkoxy, 5- to 7-membered heterocyclyl substituted with zero to 6 Ra, aryl substituted with zero to 6 Ra, mono- or bicyclic heteroaryl substituted with zero to 6 Ra, —C(O)Rb, —C(O)ORb, —C(O)NRcRc, —OC(O)Rb, —OC(O)NRcRc, —OC(O)ORd, —NRcRc, —NRbC(O)Rd, —NRbC(O)ORd, —NRbS(O)pRd, —NRbC(O)NRcRc, —NRbS(O)pNRcRc, —S(O)pRb, —S(O)pNRcRc, or —C(O)NRb(CH2)1-3NRcRc;
each Ra is independently halo, —CN, —OH, —NO2, —NH2, C1-3 alkyl, C1-3 fluoroalkyl, C2-4 alkenyl, C2-4 alkynyl, C1-3 alkoxy, C1-3 fluoroalkoxy, —(CH2)rC(O)OH, —C(O)(C1-3 alkyl), —C(O)O(C1-4 alkyl), —OC(O)(C1-3 alkyl), —NH(C1-3 alkyl), —N(C1-3 alkyl)2, —C(O)NH(C1-3 alkyl), —OC(O)NH(C1-3 alkyl), —NHC(O)NH(C1-3 alkyl), —C(?NH)(NH2), C3-7 carbocyclyl, aryl, 5- to 7-membered heterocyclyl, mono- or bicyclic heteroaryl, —O(aryl), —O(benzyl), —O(heterocyclyl), —S(O)p(C1-3 alkyl), —S(O)p(aryl), —S(O)p(heterocyclyl), —NHS(O)2(aryl), —NHS(O)2(heterocyclyl), —NHS(O)2NH(aryl), —NHS(O)2NH(heterocyclyl), —NH(aryl), —NH(heterocyclyl), —NHC(O)(aryl), —NHC(O)(C1-3 alkyl), —NHC(O)(heterocyclyl), —OC(O)(aryl), —OC(O)(heterocyclyl), —NHC(O)NH(aryl), —NHC(O)NH(heterocyclyl), —OC(O)O(C1-3 alkyl), —OC(O)O(aryl), —OC(O)O(heterocyclyl), —OC(O)NH(aryl), —OC(O)NH(heterocyclyl), —NHC(O)O(aryl), —NHC(O)O(heterocyclyl), —NHC(O)O(C1-3 alkyl), —C(O)NH(aryl), —C(O)NH(heterocyclyl), —C(O)O(aryl), —C(O)O(heterocyclyl), —N(C1-3 alkyl)S(O)2(aryl), —N(C1-3 alkyl)S(O)2(heterocyclyl), —N(C1-3 alkyl)S(O)2NH(aryl), —N(C1-3 alkyl)S(O)2NH(heterocyclyl), —N(C1-3 alkyl)(aryl), —N(C1-3 alkyl)(heterocyclyl), —N(C1-3 alkyl)C(O)(aryl), —N(C1-3 alkyl)C(O)(heterocyclyl), —N(C1-3 alkyl)CO2H —N(C1-3 alkyl)C(O)NH(aryl), —(CH2)0-3C(O)NH(heterocyclyl), —OC(O)N(C1-3 alkyl)(aryl), —OC(O)N(C1-3 alkyl)(heterocyclyl), —N(C1-3 alkyl)C(O)O(aryl), —N(C1-3 alkyl)C(O)O(heterocyclyl), —C(O)N(C1-3 alkyl)(aryl), —C(O)N(C1-3 alkyl)(heterocyclyl), —NHS(O)2N(C1-3 alkyl)(aryl), —NHS(O)2N(C1-3 alkyl)(heterocyclyl), —NHP(O)2N(C1-3 alkyl)(aryl), —NHC(O)N(C1-3 alkyl)(aryl), —NHC(O)N(C1-3 alkyl)(heterocyclyl), —N(C1-3 alkyl)S(O)2N(C1-3 alkyl)(aryl), —N(C1-3 alkyl)S(O)2N(C1-3 alkyl)(heterocyclyl), —N(C1-3 alkyl)C(O)N(C1-3 alkyl)(aryl), —N(C1-3 alkyl)C(O)N(C1-3 alkyl)(heterocyclyl), or —Si(C1-3 alkyl)3; or two Ra attached to the same carbon atom form ?O;
each Rb is independently H, C1-6 alkyl substituted with zero to 6 Rf, C3-7 cycloalkyl substituted with zero to 6 Rf, mono- or bicyclic heterocyclyl substituted with zero to 6 Rf, aryl substituted with zero to 3 Rf, or mono- or bicyclic heteroaryl substituted with zero to 3 Rf;
each Rc is independently H, C1-6 alkyl substituted with zero to 6 Rf, C3-7 cycloalkyl substituted with zero to 6 Rf, mono- or bicyclic heterocyclyl substituted with zero to 6 Rf, aryl substituted with zero to 3 Rf, or mono- or bicyclic heteroaryl substituted with zero to 3 Rf; or when attached to the same nitrogen, two Rc along with the nitrogen atom to which they are attached form 4- to 8-membered heterocyclic ring substituted with zero to 3 Rg;
each Rd is independently H, C1-6 alkyl substituted with zero to 6 Rf, C3-7 cycloalkyl substituted with zero to 6 Rf, mono- or bicyclic heterocyclyl substituted with zero to 6 Rf, aryl substituted with zero to 3 Rf, or mono- or bicyclic heteroaryl substituted with zero to 3 Rf;
each Re is independently H, C1-6 alkyl substituted with zero to 6 Rf, C1-3 haloalkyl, C3-7 cycloalkyl substituted with zero to 6 Rf, mono- or bicyclic heterocyclyl substituted with zero to 6 Rf, aryl substituted with zero to 3 Rf, or mono- or bicyclic heteroaryl substituted with zero to 3 Rf;
each Rf is independently H, halo, —OH, —CN, C1-6 alkyl substituted with zero to 6 Ra, C1-3 alkoxy, C3-7 cycloalkyl substituted with zero to 6 Ra, mono- or bicyclic heterocyclyl substituted with zero to 6 Ra, aryl substituted with zero to 3 Ra, or mono- or bicyclic heteroaryl substituted with zero to 3 Ra;
each Rg is independently H, F, —OH, —CN, C1-3 alkyl, —CF3, or phenyl;
each Rh is independently —OH or halo;
each Ri is independently H, halo, —CN, —OH, C1-3 alkyl, C1-3 fluoroalkyl, or C1-3 alkoxy; or two Ri attached to the same carbon atom of the spirocarbocyclic or spiroheterocyclic ring, form ?O; or two Ri attached to neighboring carbon atoms of the spirocarbocyclic or spiroheterocyclic ring, form a benzo ring along with the carbon atoms to which they are attached, said benzo ring substituted with zero to 4 Rf;
each Rx is independently H or C1-5 alkyl;
each Ry is independently C1-5 alkyl;
each p is independently zero, 1, or 2;
q is zero, 1, or 2; and
each r is independently zero, 1, 2, 3, or 4.

US Pat. No. 10,335,388

COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF

PELOTON THERAPEUTICS, INC...

1. A method of treating cancer in a subject in need thereof, comprising administering to said subject an effective amount of a HIF-2? inhibitor in combination B with an immunotherapeutic agent, wherein the cancer is selected from the group consisting of melanoma, renal cell carcinoma, and colorectal cancer, wherein the immunotherapeutic agent is a PD-1 inhibitor or a CTLA-4 inhibitor, and wherein the HIF-2? inhibitor is a compound of Formula I-C:
or a pharmaceutically acceptable salt thereof, wherein:
X is CR5 or N;
Y is CR6 or N;
Z is —O—, —S—, —C(HR7)—, —N(R8)— or absent;
R1 is alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl or cyano;
R4 is nitro, halo, cyano, alkyl, cycloalkyl, heteroaryl, carboxyl, sulfinyl, sulfonamidyl, sulfonyl or sulfoximinyl;
R5, R6, R7 and R8 are independently hydrogen, halo, hydroxy, cyano, alkyl or alkoxy;
R11 is hydrogen, halo, hydroxy, alkoxy or amino;
R12 is hydrogen, alkyl, alkenyl or alkynyl; or R11 and R12 in combination form oxo or oxime;
each of R13 is independently selected from the group consisting of hydrogen, fluoro, chloro, hydroxy, alkyl and heteroalkyl; or two R13s and the carbon atom(s) to which they are attached form a 3- to 8-membered cycloalkyl or heterocycloalkyl moiety; and
n is 0, 1, 2, 3 or 4.

US Pat. No. 10,335,386

LIPID COMPRISING POLYUNSATURATED FATTY ACIDS

COMMONWEALTH SCIENTIFIC A...

1. Canola oil extracted from Brassica napus seed, comprising a total fatty acid content which comprises docosahexaenoic acid (DHA, 22:6?3), wherein the DHA is present at a level of between 7% and 20% of the total fatty acid content, wherein at least 70% of the DHA in the total fatty acid content is esterified at the sn-1 or sn-3 position of triacylglycerol (TAG) in the canola oil.

US Pat. No. 10,335,383

OAT FRACTIONS WITH ENHANCED AVENANTHRAMIDE CONCENTRATION AND METHODS OF MAKING

The Quaker Oats Company, ...

1. A food product comprising an infrared-treated oat flour made by exposing a pre-treatment oat flour to infrared energy so that the infrared-treated oat flour has a higher concentration of total Avenanthramides than the pre-treatment oat flour,wherein the amount of Avenanthramides in the food product is sufficient to provide a health benefit to a human upon oral ingestion of the food product by the human,
wherein the concentration of total Avenanthramides in the infrared-treated oat flour is higher than the concentration of total Avenanthramides that occurs naturally in the pre-treatment oat flour,
wherein the infrared-treated oat flour has been treated by exposure to infrared energy so that the concentration of total Avenanthramides in the infrared-treated oat flour is increased by at least 5 wt. % relative to the concentration of total Avenanthramides in the pre-treatment oat flour, wherein the pre-treatment oat flour is untreated for Avenanthramides enhancement,
wherein the exposure includes exposing the pre-treatment oat flour to from 2 to 15 kJ of infrared energy per gram of the pre-treatment oat flour,
wherein the infrared-treated oat flour is untreated with enzymes to increase the concentration of Avenanthramides, and
wherein the infrared-treated oat flour is untreated with fungal agents to increase the concentration of Avenanthramides.

US Pat. No. 10,335,382

USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY

THE BOARD OF REGENTS OF T...

1. A cystathionine-?-synthase (CBS) inhibitor having a chemical structure of Formula I,
wherein R1 is a 3-pentyl group, wherein the compound inhibits CBS.

US Pat. No. 10,335,380

COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS

CNIC Fundacion Centro Nac...

1. A method of treating and/or preventing MPN (myeloprofilerative neoplasms) in a patient, comprising administering to said patient a therapeutically effective amount of a compound of Formula 1:
wherein R1 is selected from hydrogen and halogen; and
wherein R2 is an aralkyl, being able to be substituted in the aryl part and/or in the alkyl part, or a radical selected from:

US Pat. No. 10,335,379

ORAL DOSAGE FORMS OF KETAMINE

Develco Pharma Schweiz AG...

1. An oral dosage form comprising ketamine or a pharmaceutically acceptable salt or solvate thereof,wherein the dosage form provides an in vitro release of ketamine, when measured according to the USP Basket Method I in 0.1M HCl at 37° C. at 100 rpm, of 0 to 40% after 2 hours, of 10 to 70% after 4 hours, of 30 to 85% after 6 hours and of 45 to 100% after 8 hours,
wherein the dosage form provides an in vitro release of ketamine, when measured according to the USP 1 Basket Method in 0.1M HCl at 100 rpm, after one hour at 37° C., in an aqueous solution containing 20% by volume of ethanol, in a ratio of less than 2:1 relative to the amount of ketamine released, so measured, after one hour at 37° C. in an ethanol-free aqueous solution,
wherein the dosage form is a multi-particulate controlled release tablet,
wherein the tablet comprises pellets each containing
i) a core comprising
1 to 30 wt. % inert beads,
5 to 400 mg and 1 to 40 wt. % ketamine hydrochloride,
0.01 to 10 wt. % binder, and
0 to 10 wt. % glidant, and
ii) a release control layer comprising
1 to 40 wt. % of a release control substance coated upon the core, wherein the release control substance is a water insoluble polymer,
0.01 to 10 wt % pore builder,
0.01 to 10 wt. % plasticizer, and
0 to 15 wt. % glidant, and
wherein the pellets are contained in an external phase comprising
carboxymethyl cellulose, optionally in the form of a salt, as a pharmaceutically acceptable excipient,
20 to 85 wt. % filler,
0 to 3 wt. % lubricant, and
0 to 5 wt. % glidant,
wherein the tablet optionally comprises an external film coating, and
wherein all wt. % are based on the total weight of the tablet, without the film coating.

US Pat. No. 10,335,374

TABLET COMPOSITION FOR ANTI-TUBERCULOSIS ANTIBIOTICS

University System of Geor...

1. A pharmaceutical composition comprisingi. one or more front line antibiotics used in the treatment of the bacterial infection Mycobacterium tuberculosis;
ii. sucrose, wherein its mass percent is a minimum of about one percent and a maximum of fifty percent of the total composition mass;
iii. copper (Cu), which is present in an amount from at least about one percent to about forty percent of the total mass of the composition; and
iv. a polyethylene glycol (PEG) polymer wherein its mass percent is a minimum of at least five percent and a maximum of 90% of the total composition mass.

US Pat. No. 10,335,372

COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES

Jacob G. Appelbaum, Gain...

1. A method for treating a viral disease in a subject, the method comprising:administering to the subject a composition for destruction of targeted nucleic acids inside biological cells, the composition comprising:
a core carrier comprising a plurality of first multivalent molecular scaffolds and a plurality of second multivalent molecular scaffolds, each of the first and second multivalent molecular scaffolds being covalently bound to the core carrier, each first and second multivalent molecular scaffold comprising a polymer,
at least one of the first multivalent molecular scaffolds further comprising a plurality of cell membrane permeating peptides covalently bound to the first multivalent molecular scaffold for effective internalization of the composition into cytoplasm of the biological cells, wherein the first multivalent molecular scaffolds are nuclease-free,
at least one of the second multivalent molecular scaffolds comprising a plurality of nucleic acid targeting ligands covalently bound to the second multivalent molecular scaffold that is capable of binding specific sequences on targeted nucleic acids inside the biological cells, at least one nuclease covalently bound to the second multivalent molecular scaffold that is capable of destruction of the targeted nucleic acids that are bound to the nucleic acid targeting ligands inside the biological cells.

US Pat. No. 10,335,361

COSMETIC PROCESS FOR MAKING-UP AND/OR CARING FOR THE SKIN AND/OR THE LIPS

1. A cosmetic process for making up and/or caring for skin and/or lips, comprising applying a cosmetic composition to the skin and/or the lips, the cosmetic composition comprising, in a physiologically acceptable medium:supramolecular polymer having the formula:

the supramolecular polymer being present in an amount in a range of from 0.3 to 40% by weight relative to a total weight of the composition; and
at least one hydrophobic film-forming polymer in an amount in a range of from 0.2 to 20% by weight relative to a total weight of the composition, the hydrophobic film-forming polymer being a vinyl polymer bearing a carbosiloxane dendrimer-based unit having a formula selected from the group consisting of:

US Pat. No. 10,335,358

HAIR COSMETIC

KAO CORPORATION, Tokyo (...

1. A hair cosmetic comprising ingredients (A) and (B):(A) from 0.37 to 5 mass % of a cationic polymer having a charge density of 5.0 meq/g or more and 6.2 meq/g or less; and
(B) from 0.61 to 2.52 mass % of an anionic polysaccharide derivative wherein a part of the hydrogen atoms of the hydroxyl group of a polysaccharide compound having a constituent unit represented by formula (1) are substituted with —(CH2)mCOO? group, wherein m is an integer of 1 to 5, at an average substitution degree of from 0.7 to 0.85 per constituent unit, and wherein optionally a part of the hydrogen atoms of the remaining hydroxyl groups are substituted with linear or branched C1-40 alkyl groups, alkylene groups, or a combination thereof;
wherein:
a mass ratio of ingredient (A) to ingredient (B), (A)/(B), is from 0.2 to 1.5;
a viscosity of ingredient (B) in a 2 mass % aqueous solution at 25° C. is from 3 mPa·s to 298 mPa·s; and
formula (1) is:
wherein each R?, independently, represents a C2-4 linear alkylene group optionally substituted with a hydroxyl group or a C2-4 branched alkylene group optionally substituted with a hydroxyl group, and n represents a number by which the average number of added moles of R?O per constituent unit is 0 to 10.

US Pat. No. 10,335,351

PERSONAL CARE ARTICLES AND METHODS

1. A compliant personal cleansing article, comprising:a) cleansing composition, comprising a rheology modifier and from about 10% to about 70%, by weight of the composition, of a synthetic surfactant; and
b) a water penetrable first substrate surrounding the composition; wherein the article has a compliance of about 1.50 kg/mm or less.

US Pat. No. 10,335,350

PACIFIER WHICH HELPS WEAN TODDLERS OFF PACIFIERS

1. A pacifier, intended for use with infants of suitable age to wean a child from continued pacifier use without anger, anxiety or stress, comprising:a) a teat structure for allowing the child to suck upon it;
b) a mouth shield arranged generally perpendicularly to the teat and joined therewith so as to be generally inseparable therefrom, said mouth shield defining an outermost edge of the pacifier, said mouth shield comprising apertures extending through said mouth shield, said apertures being disposed radially outward from the teat structure; and
c) a flexible sheet having bristle structures projecting therefrom, said bristle structures covering an entire surface of said mouth shield from an outermost edge of the mouth shield to a position adjacent the teat, wherein said flexible sheet comprises apertures extending through said flexible sheet, wherein the apertures of the mouth shield are axially aligned with said apertures of the flexible sheet, wherein said bristle structures project in the same direction as the teat to slightly irritate the face and mouth of the child during use thereby discouraging continued use of the pacifier.

US Pat. No. 10,335,349

PRESCRIPTION DRUG ABUSE PREVENTION SYSTEM

Addinex Technologies, Inc...

1. A container for restricting access to controlled objects comprising:a housing with a central axis, a top, and a bottom, and having an access port therein;
an object storage drum within the housing, the drum being rotatable about the axis relative to the housing and having a plurality of dispensing positions including a start dispensing position and an end dispensing position, each dispensing position allowing access to a respective dispensing portion of the drum through the access port;
a combination element rotatable about the axis relative to the housing, the combination element being rotationally lockable to the drum and having a surface with a plurality of channels formed therein;
a plurality of pegs engaging the channels in the surface, each respective peg being movable between a respective plurality of predefined peg positions, the housing having indicia thereon indicating the respective pluralities of predefined peg positions;
when the combination element is rotationally locked to the drum the plurality of channels defining for each respective peg a traversal path through which the respective peg can travel as the drum is rotated from the start dispensing position to the end dispensing position, the traversal path for each respective peg requiring the respective peg to be in a first predefined peg position to permit rotation of the drum between a respective first pair of adjacent dispensing positions and a second predefined peg position to permit rotation of the drum between a respective second pair of adjacent dispensing positions, wherein rotation of the drum requires the plurality of pegs to follow the respective traversal paths;
the particular positions of the plurality of pegs required to permit rotation of the drum from a current dispensing position to a next dispensing position defining a transition peg combination for the current dispensing position.

US Pat. No. 10,335,348

FILLING NEEDLE FOR USE IN A TUBE LAYER FOR TRANSFERRING A FLOWABLE MEDIUM, IN PARTICULAR A PHARMACEUTICAL PRODUCT

1. A filling needle for use in a tube set for transferring a flowable medium, the filling needle comprising:a needle end for temporary insertion into a filling vessel;
a connector end for connecting the filling needle to a filling device via which the medium can be supplied to the filling needle;
an inner tube layer made of silicone, defining an inner tube lumen;
an outer reinforcing tube layer made of a plastic reinforcing material, encasing the inner tube lumen; and
a bonding agent between the inner tube layer and the reinforcing tube layer,
wherein the bonding agent includes bonding bodies which mechanically bond the two tube layers, and
wherein the filling needle on the whole is made entirely of plastic.

US Pat. No. 10,335,347

CLOSING SYSTEM FOR A CONTAINER

Becton Dickinson France, ...

1. A closing system for a container, the closing system comprising:a cap comprising a skirt and a transversal wall provided with an access port;
a cover parallel to the cap, the cover comprising a proximal face having a protrusion extending therefrom and a proximally curved pushing surface extending from the proximal face, said proximally curved pushing surface and said protrusion each extending from the proximal face, but offset from one another; and
a hinge allowing a planar rotation of the cover regarding the cap from a first position closing the access port to a second position giving access to the access port,
wherein the cover further comprises a front portion, a rear portion, a first side, and a second side, the rear portion located opposite the front portion, and the first side located opposite the second side, wherein the pushing surface and the protrusion are located on the first side of the cover and,
wherein the pushing surface and the protrusion are positioned with respect to each other such that the protrusion is located closer to the hinge than the pushing surface to facilitate rotation of the cover with respect to the cap.

US Pat. No. 10,335,346

OPTICAL TECHNIQUES FOR THE MEASUREMENT OF CHEST COMPRESSION DEPTH AND OTHER PARAMETERS DURING CPR

PHYSIO-CONTROL CANADA SAL...

1. A device for monitoring chest compressions during the administration of cardiopulmonary resuscitation to a patient, comprising:a three-dimensional image optical sensor attached to a wrist band configured to be worn around a wrist of a rescuer administering cardiopulmonary resuscitation to the patient, the optical sensor configured to sense a distance, for a plurality of pixels of the optical sensor, between the optical sensor and an object in an environment surrounding the optical sensor, the distance sensed throughout motion of a chest compression administered by the rescuer during cardiopulmonary resuscitation and the object in the environment monitored for changes that are related to the depth of the administered chest compressions, the optical sensor positioned to move with the motion of the chest compression;
processing circuitry configured to receive the sensed distance from optical sensor and further configured to:
generate a depth map from the sensed distance between the optical sensor and the object in the environment of the sensor; and
extract depth information of the chest compression based on the depth map.

US Pat. No. 10,335,345

VIBRATION DEVICE USING SOUND PRESSURE, AND HUMAN BODY STIMULATION APPARATUS COMPRISING SAME

EVOSONIC CO., LTD., Wonj...

1. A vibration device for generating vibration using sound pressure, the vibration device comprising:a lower body being open at a top thereof, and defining an accommodation space therein;
a lower bracket being open at a top and a bottom thereof, and provided in the accommodation space of the lower body;
a magnetic body fixedly provided on a bottom surface of the lower body to generate a magnetic force;
a bobbin provided in the lower bracket to be located above the magnetic body;
a voice coil provided on an outer circumference of the bobbin to interact with the magnetic body;
a damper provided on an upper surface of the bobbin, coupled to an upper surface of an edge of the lower bracket, and vertically generating vibration by interaction between the magnetic body and the voice coil;
a connection member coupled at a lower end thereof to a central portion of the damper and a central portion of the upper surface of the bobbin, and coupled at an upper end thereof with a vibration probe for stimulating a human body, thus transmitting vibration from the damper to the vibration probe;
an upper body covering an open top of the lower body, the connection member being inserted into a center on an upper surface of the upper body; and
an upper bracket being open at a bottom thereof, and accommodated in an internal space of the upper body to be coupled with the lower bracket, the connection member being inserted into an upper surface of the upper bracket.

US Pat. No. 10,335,344

MASSAGE APPLIANCE, MANUFACTURING METHOD THEREOF, AND MANUFACTURING APPARATUS

TENGA CO., LTD., Tokyo (...

1. A manufacturing method of a massage appliance comprising:providing a motor, a vibrating piece configured to be driven by the motor, and a case configured to accommodate the motor and the vibrating piece and including a case opening at least in one place;
accommodating the motor and the vibrating piece in the case;
preparing a soft cover which includes a cover opening at a position corresponding to the case opening, the soft cover configured to surround an outer surface of the case;
coating the soft cover on the outer surface of the case to make the case opening communicate with the cover opening;
forming a space between the outer surface of the case and an inner surface of the soft cover by tightly fixing a peripheral edge of the cover opening over the entire peripheral of a peripheral edge of the case opening;
introducing a negative pressure into the space;
injecting a liquid resin as an undiluted solution of a soft resin into the space, the soft resin being interposed between the outer surface of the case and the soft cover, and being of a material which is more flexible than the soft cover, and being thicker than the soft cover; and
curing the liquid resin to become the soft resin.

US Pat. No. 10,335,343

METHOD AND DEVICE FOR TREATING FEMALE PELVIC NERVE DYSFUNCTION

ParaPatch, Inc., Campbel...

1. A device adapted for providing an inhibitory effect on a bladder of a female person, comprising a patch having a substantially planar skin-contacting surface and sized and configured to be secured directly over and covering a clitoris without covering a urethra of said person, the patch formed of a backing sheet of flexible material with an adhesive layer comprising an adhesive on one side of the backing sheet, the adhesive layer removably connected to a release layer, the patch configured when applied to stimulate the clitoris to inhibit bladder discharge.

US Pat. No. 10,335,342

METHOD, SYSTEM, AND APPARATUS FOR TREATMENT OF BINOCULAR DYSFUNCTIONS

New Jersey Institute of T...

1. A method for remediating visual symptoms in a user with binocular dysfunction, the method comprising:rendering a visual therapy video game on one or more displays;
controlling accommodative and proximal vergence stimulation of a user's eyes via the visual therapy video game; and
asymmetrical stimulating to a left eye or a right eye of the user via the visual therapy video game based on peak velocity differences between the left and right eyes.

US Pat. No. 10,335,341

WALKING ASSISTANCE METHOD AND APPARATUS

Samsung Electronics Co., ...

1. A control device configured to control a vibrator including at least a first vibrating element and a second vibrating element associated with different portions of a sole of a user, the control device comprising:a gait data receiver configured to,
receive pressure data indicating information on a pressure applied to the sole of the user, and
receive hip joint angle data indicating a hip joint angle of the user;
a gait motion estimator configured to estimate a gait motion of the user based on the pressure data; and
a feedback provider configured to,
estimate a center of pressure (COP) of the sole based on the pressure data and the hip joint angle data,
adjust an intensity of a first vibration and a second vibration based on a shift in the COP of the sole with respect to the gait motion such that, during a first step of a stride, the intensity of the first vibration continuously increases and the intensity of the second vibration continuously decreases, and
control the vibrator to vibrate the sole of the user such that the first vibration is applied to the first vibrating element and the second vibration is applied to the second vibrating element.

US Pat. No. 10,335,340

MOBILE DENTAL INTELLIGENCE CENTER

Dr. Kevin T. Prince, Hon...

1. A portable dental and medical unit comprising:a wheelbase;
a plurality of 360 degree rotatable wheels extending from the wheelbase and configured to movably support the unit on an underlying support surface;
a central support beam extending upward from the wheelbase;
a rechargeable power supply positioned within a power supply compartment and a retractable wall plug mounted on the central support beam adjacent said wheelbase;
a cylindrical housing supported by the central support beam and spaced apart from the wheelbase, wherein the cylindrical housing is vertically adjustable with respect to the wheelbase by a unit height adjustor;
the cylindrical housing has a bottom and a top and comprises series of elements including:
a waste water reservoir with a reservoir drain positioned adjacent the bottom;
a clean water reservoir with a reservoir drain position adjacent the bottom;
a suction pump positioned adjacent said waste water reservoir or said clean water reservoir;
an air compressor positioned adjacent said waste water reservoir or said clean water reservoir;
a mouthwash reservoir positioned adjacent said suction pump;
a toothbrush rinser positioned adjacent said mouth wash reservoir;
a biofilm contamination sensor located near the waste water reservoir;
a water pump;
a unit control module; and
a unit supply platform positioned within a unit supply storage compartment adjacent the mouth wash reservoir, toothbrush rinser and unit control module and near a top of the cylindrical housing, wherein the unit supply platform includes a series of inter-unit supply line attachment ports and a series of USB ports;
a protrusion, including dual solar panels positioned on a surface thereof, extends upward from the top of the cylindrical housing and includes a foldable handle with slip-resistant grip mounted thereto and a 360 degree swivel digital display mounted thereto;
wiring and inter-unit supply lines and hoses extend through the central support beam and are configured to attach to at least one of the series of elements, the rechargeable power supply or an electric toothbrush, a computer monitor or an air-water syringe and connector;
wherein the 360 degree swivel digital display is configured to display information measured by one of said series of elements or an external health monitoring device including a digital blood pressure cuff, a digital thermometer, a digital pulse oximeter or a digital intra oral and extra oral camera connected to one of the series of USB ports.

US Pat. No. 10,335,339

PORTABLE EXAMINATION CHAIR

1. A pivoting examination chair mechanism for an examination chair related to a substantially immovable examination tool, comprising:a rotation mechanism portion rotating about a first vertical axis;
a rotation arm integral with, and extending from, said rotation mechanism portion; and,
a chair support portion attached proximate a distal end of said rotation arm offset from a rotating base portion including a chair gimbal located on a set of legs extending upwards from said rotation arm, wherein said chair gimbal rotates around a second vertical axis and wherein said first vertical axis and said second vertical axis are substantially parallel to one another for moving said rotation arm through 180°, so that said pivoting examination chair is movable about said first vertical axis for providing a clear access area to said substantially immovable examination tool.

US Pat. No. 10,335,338

APPARATUS FOR APPLYING MULTI-DIMENSIONAL TRACTION TO THE SPINAL COLUMN

Nichols Therapy Systems L...

1. A physical medicine table for treating a patient's spine comprising:a. a frame having a longitudinal axis and a transverse axis;
a plurality of support portions that are configured to receive a patient, wherein the plurality of support portions are attached to the frame and selectively spaced apart along the longitudinal axis of the frame;
c. wherein a first support portion comprises:
i. a first longitudinal movement subframe slidably mounted to the frame;
ii. a first lateral movement subframe slidably mounted to the first longitudinal movement subframe and configured to move in the transverse axis;
iii. a rotational adjustment subframe mounted to the first lateral movement subframe, the rotational adjustment subframe configured to selectively rotate;
d. a traction system comprising:
i. a first lateral actuator centrally mounted to the first longitudinal movement subframe and centrally disposed under the rotational adjustment subframe;
ii. wherein the traction system is configured to exert a first lateral force upon the first lateral movement subframe without rotating the first lateral movement subframe and without rotating the first support portion, wherein the first lateral force is perpendicular to the longitudinal axis of the frame, and the traction system is further configured to exert a longitudinal force upon at least one of the plurality of support portions; and
e. a control system that selectively controls the first lateral force and the longitudinal force exerted by the traction system.

US Pat. No. 10,335,337

INCUBATOR WITH THERMOREGULATING ARRANGEMENT FOR NEWBORNS SUFFERING FROM PATHOLOGIES

1. An incubator with a thermoregulating arrangement for newborns suffering from pathologies, comprising a closed compartment which externally has a plurality of openings and an access door, while internally it is comprised of a horizontal partition defining an upper part adapted to receive a newborn in a resting position and a lower part provided with thermoregulating means that produce air flows, adapted to maintain the newborn at required temperatures, said upper part comprises an outer hood separated from an inner hood with an upper external circulation channel being defined therebetween, whereinthe upper external circulation channel being in fluid communication with said lower part through a low pressure lower external circulation channel and a high pressure lower external circulation channel,
the thermoregulating means comprise a heating resistor, a baffle and a cold/heat generator,
said partition is provided with a first head and a second head and at least one mattress tray between both heads,
the first head includes a low pressure internal air channel and the second head includes a high pressure internal air channel, with the low pressure internal air channel and the high pressure internal air channel being arranged at opposite sides of the at least one mattress tray and the thermoregulating means and in fluid communication with opposite ends of the upper part defining an internal air flow flowing from said high pressure internal air channel towards the low pressure internal air channel and extending underneath and concentrically to the inner hood and spaced apart from the at least one mattress tray, thus forming a bubble around the at least one mattress tray.

US Pat. No. 10,335,336

INCUBATOR

Atom Medical Corporation,...

1. An incubator comprising:an incubator base that is provided on a main strut;
a bed base that is provided on the incubator base and on which a mattress is placed; and
a cassette tray accommodation space which is formed between the incubator base and the bed base, wherein the cassette tray accommodation space comprises at least three tray loading/unloading ports selected from: a front tray loading/unloading port, a rear tray loading/unloading port, a left tray loading/unloading port, and a right tray loading/unloading port.

US Pat. No. 10,335,335

AIR MATTRESS FOR GATCH BED

Paramount Bed Co., Ltd., ...

1. An air mattress placed on a plurality of bottoms including a back bottom, comprising:a plurality of air cells extending to a bed width direction and being arranged in parallel in a bed longitudinal direction;
an air supplying unit for performing supply and discharge of air for each of the air cells; and,
a control unit that inflates and deflates the air cells by increasing and decreasing a pressure of air to be supplied to each of the air cells, wherein
the control unit is configured to:
detect a back tilt angle of the back bottom;
inflate an air cell, of the plurality of air cells, that is in a deflated state when the back tilt angle has reached a first angle; and
perform, after the air cell has been inflated, an inflating and deflating operation of a proper subset of the air cells until a rising operation of the back bottom ends.

US Pat. No. 10,335,334

EMERGENT SITUATION NOTIFICATION DURING TRANSPORT OF A PATIENT SUPPORT APPARATUS

Hill-Rom Services, Inc., ...

1. A patient-support status system comprisinga patient support apparatus adapted to support a patient thereon, the patient support apparatus including control circuitry including memory storing the identity of the patient support apparatus,
a user interface coupled to the control circuitry and monitoring for a user input associated with an emergent situation of the patient during transportation of the patient on the patient support apparatus,
a location-detection system coupled to the control circuitry of the patient support apparatus, the location detection system communicating with location identifiers in a healthcare facility to provide a real-time location of the patient support apparatus as the patient support apparatus moves through the healthcare facility, and
a transceiver coupled to the control circuitry, the transceiver communicating the patient support apparatus identity and the real-time location to a remote computer in response to receipt of the user input.

US Pat. No. 10,335,333

MECHANICS OF THE BED SIDERAIL

LINET SPOL. S R.O., Slan...

1. A bed comprising:a frame,
a patient support connected to the frame,
at least two posts connected on one side of the bed to the frame of the bed,
at least one siderail with a frame,
a locking mechanism positioned between the two posts and at least one part of the frame of the siderail, and
a linkage for manipulation of the siderail with respect to the patient support, the linkage comprising a first arm and a second arm; the first arm having a first end connected in a rotating manner by a fixed pivot to the frame of the bed and a second end connected in a rotating manner to a center of the second arm; the second arm having a first end connected in a rotating manner by a sliding coupling to the frame of the bed and a second end connected in a rotating manner to the bed siderail.

US Pat. No. 10,335,332

TOP BAR ACCESSORY FOR WALKER

GANM, LLC, Paris, TN (US...

1. An accessory package for a walker, the accessory package comprising:a cross bar having opposite first and second ends; and
first and second pivot connections configured to connect to the respective first and second ends of the cross bar to the respective laterally opposite sides of a frame of the walker, each of the pivot connections comprising;
an eyelet portion adapted and configured to receive one of the first and second ends of the cross bar, the eyelet portion having a stem with a stem axis extending along a length of the stem; and
an upright piece adapted and configured to be removable attachable to the respective lateral opposite sides of the frame with mechanical fasteners, the upright piece having an outer shape formed to conform to a framework of the walker such that when the upright piece is removably connected to the framework of the walker with the mechanical fasteners, the upright piece is constrained from relative movement with the framework of the walker, the upright piece being adapted and configured to receive the stem and permit adjustment of the length of the stem received within the upright piece along the stem axis, the upright piece being adapted and configured to allow relative rotation of the stem within the upright piece about the stem axis thereby allowing pivoting of the upright piece about the stem axis;
further comprising a locking cap adapted and configured to be fitted to the respective first and second ends of the cross bar to secure the cross bar within the eyelet portion.

US Pat. No. 10,335,331

POWERED WHEELCHAIR, WHEELCHAIR POWERING DEVICE AND METHOD

INVENTIT PRODUCTS, INC., ...

1. A wheelchair powering device configured for integration with a foldable wheelchair, the device comprising:an attachment mechanism configured to attach the powering device to the wheelchair;
a motor;
a roller member operatively coupled to the motor such that operation of the motor drives rotation of the roller member; and
an adjustment mechanism operatively coupled to the roller member, the adjustment mechanism being configured to control movement of the roller member into and out of contact with a wheel of the wheelchair,
wherein the adjustment mechanism includes a lever, wherein the roller member passes through a roller member bracket, and wherein the lever is operatively coupled to the roller member bracket such that adjustment of the lever causes rotation of the roller member bracket to displace the roller member,
wherein the wheelchair powering device is configured to provide for the wheelchair to be folded with the wheelchair powering device integrated with the foldable wheelchair, and
wherein, upon integration of the wheelchair powering device with the wheelchair, the wheelchair is configured to be powered interchangeably by both operation by the powering device and manual operation.

US Pat. No. 10,335,330

MOTOR-DRIVEN CHAIR STEERED BY SEAT ROTATION

TRAVELSYS4U LTD., Ramat ...

1. A motor-driven chair for propelling a user over an underlying surface, the chair comprising:(a) a seat element having support surfaces for supporting the user sitting in a seat-facing direction;
(b) a seat pole extending downwards from said seat element for supporting said seat element, said seat pole defining a vertical axis;
(c) a drive wheel rotatable about a horizontal axis of rotation so as to define a direction of forward motion perpendicular to said axis of rotation, said drive wheel being located beneath said seat element substantially on said vertical axis, said drive wheel being mechanically linked to said seat pole so as to maintain said direction of forward motion aligned with said seat-facing direction so that rotation of said seat element about said vertical axis causes a corresponding rotation of said direction of forward motion;
(d) a motor in driving connection to said drive wheel so as to drive said drive wheel to rotate about said horizontal axis of rotation, and thereby propel the chair in the seat-facing direction;
(e) a stabilizer assembly mechanically linked to said seat pole, said stabilizer assembly comprising a set of stabilizer wheels mounted on a support structure for supporting said seat pole in a vertical orientation, said stabilizer assembly allowing rotation of said seat pole about said vertical axis relative to said support structure; and
(f) a suspension arrangement associated with said seat pole, said drive wheel and said stabilizer assembly, said suspension arrangement being configured to distribute a load of the user sitting stably on said seat element so as to maintain a predefined range of proportions between a load supported by said drive wheel and a load supported by said stabilizer wheels.

US Pat. No. 10,335,329

POWERED COTS

Ferno-Washington, Inc., ...

1. A cot comprising:a support frame comprising a front end, a back end and a pair of parallel lateral side members extending between the front end and the back end, the pair of parallel lateral side members defining tracks therein;
a pair of front legs each of which is slidingly engaged with and pivotally coupled to the support frame through a respective front carriage member that is disposed within one of the tracks, wherein each front leg comprises at least one front wheel;
a pair of back legs each of which is slidingly engaged with and pivotally coupled to the support frame through a respective back carriage member that is disposed within one of the tracks, wherein each back leg comprises at least one back wheel;
a front actuator sensor that detects whether the pair of front legs are in contact with a surface beneath the support frame or the pair of front legs are out of contact with the surface beneath the support frame;
a back actuator sensor that detects whether the pair of back legs are in contact with the surface beneath the support frame or the pair of back legs are out of contact with the surface beneath the support frame; and
a cot actuation system responsive to a received signal from at least one of the front and back actuator sensors during at least one of loading the cot onto or unloading the cot from a loading surface, the cot actuation system comprising a front actuator that is cooperative with each front carriage member to move the at least one wheel of each of the front legs relative to the at least one wheel of each of the back legs during at least one of loading the cot onto or unloading the cot from a loading surface and a back actuator that is cooperative with each back carriage member to move the at least one wheel of each of the back legs relative to the at least one wheel of each of the front legs during at least one of loading the cot onto or unloading the cot from a loading surface.

US Pat. No. 10,335,328

HARNESS SYSTEM FOR PATIENT TRANSPORT APPARATUS

Stryker Corporation, Kal...

1. A patient transport apparatus for transporting a patient, said patient transport apparatus comprising:a support structure having a base and a patient support surface;
wheels coupled to said base;
a harness system operable by a user to secure the patient to said patient support surface, said harness system comprising:
a plurality of harness assemblies configured to be coupled to said support structure, each of said harness assemblies comprising:
a connector; and
a flexible restraint member coupled to said connector, said flexible restraint member comprising a fabric and a coating covering said fabric, said flexible restraint member comprising stitches securing first and second sections of said fabric together at a joint,
wherein said fabric and said stitches are configured to be unexposed to contaminants during use.

US Pat. No. 10,335,327

SPINE BOARD

1. A spine board, comprising: a backboard, wherein at least a portion of the backboard is transparent; and a mirror that is coupled to the backboard via one or more coupling devices, the mirror being substantially the same size as the backboard, the coupling devices facilitating the mirror being at least partially removable from the backboard, and the mirror having a reflective surface facing the backboard when the mirror is coupled to an underside of the backboard, wherein at least partially removing the mirror from the backboard facilitates visual assessment of a posterior surface of a patient occupying the spine board using a reflection, via the mirror, of the posterior surface of the patient through the portion of the backboard that is transparent.

US Pat. No. 10,335,326

SMART NURSING CONSUMABLE AND PHYSIOLOGICAL MONITORING DEVICE USING THE SAME

Sinopulsar Technology Inc...

1. A smart nursing consumable, comprising:an absorbent body, comprising a water-absorbing layer and a water draining layer disposed above the water-absorbing layer; and
a sensor module, disposed on the water draining layer and comprising a plurality of wires, a first porous sheet, a second porous sheet and a conductive pad, wherein the wires are disposed between the first porous sheet and the second porous sheet, the first porous sheet is disposed adjacent to the water-absorbing layer, and the conductive pad is connected to the wires through pores of the second porous sheet.

US Pat. No. 10,335,325

ERGONOMIC DISPOSABLE ABSORBENT GARMENT

Advanced Absorbent Techno...

1. A disposable absorbent undergarment configured to be worn by a person, said undergarment having a central longitudinal axis and comprising:an absorbent core assembly centered on said central longitudinal axis and having a pair of sides extending parallel to said central longitudinal axis, said absorbent core assembly being of a predetermined width between said sides, and being configured for absorbing fluid from the person; and
a chassis comprising a sheet of a cloth-like, non-woven, breathable material, said sheet having an inner surface, a front section, a back section, and an crotch section located between said front section and said back section, said front section including a top front edge, a pair of front side edges defining therebetween the width of said front section, and a plurality of linear elastic threads extending parallel to said top front edge and to each other completely across said width of said front section from one of said pair of front side edges to the other of said pair of front side edges, said back section including a top back edge, a pair of back side edges defining therebetween the width of said back section, and a plurality of linear elastic threads extending parallel to said top back edge and to each other completely across said width of said back section from one of said pair of back side edges to the other of said pair of back side edges, said crotch section comprising a pair of central side edges defining therebetween the width of said crotch section, the maximum width of said crotch section being less than said width of said front and back sections, said crotch section having and a plurality of linear elastic threads extending parallel to said front top edge, to said back top edge, and to each other completely across said width of said crotch section from one of said pair of central side edges to the other of said pair of central side edges, respective ones of said front side edges being secured to respective ones of said back side edges, each of said pair of central side sections comprising an ergonomically shaped recess forming a respective leg opening for the person, said recesses being spaced apart from each other by a distance which is greater than said predetermined width of said absorbent core assembly, said absorbent core assembly being secured on said inner surface of said chassis at said crotch section and centered on said central longitudinal axis between said respective leg openings with plural ones of said plurality of linear elastic threads of said crotch section at said absorbent core assembly being cut into a plurality of separated segments extending across the entirety of said absorbent core assembly from a point adjacent one of said pair of sides to a point adjacent the other of said pair of sides whereupon some of said plurality of separated segments extend through said central longitudinal axis and others of said plurality of separated segments are located immediately adjacent said central longitudinal axis, said plurality of separated segments being configured so as not to tend to collapse or buckle said absorbent core assembly when said garment is worn by the person.

US Pat. No. 10,335,324

ABSORBENT ARTICLES WITH CHANNELS

1. An absorbent article comprising:a front waist region;
a rear waist region;
a crotch region positioned intermediate the front waist region and the rear waist region;
a liquid permeable material;
a liquid impermeable material;
an absorbent core disposed at least partially intermediate the liquid permeable material and the liquid impermeable material and comprising an absorbent material, wherein the absorbent material is positioned within a core wrap, wherein the core wrap forms a C-wrap, wherein the absorbent material comprises at least 85% of superabsorbent polymers by weight of the absorbent material, wherein the absorbent core defines a first channel substantially free of the superabsorbent polymers, wherein the first channel extends substantially through the thickness of the absorbent material, wherein a first side of the core wrap is joined to a second side of the core wrap in a portion of the first channel, and wherein the first channel extends from the front waist region to the rear waist region;
a liquid management system positioned at least partially intermediate the liquid permeable material and the core wrap, wherein the liquid management system is substantially free of any superabsorbent polymers; and
a liquid distribution system, wherein the liquid distribution system defines a second channel, wherein the liquid distribution system is positioned intermediate the liquid management system and the core wrap, and wherein the second channel extends substantially through the thickness of the liquid distribution system.

US Pat. No. 10,335,323

METHOD FOR PRODUCING DISPOSABLE WORN ARTICLE

Zuiko Corporation, Osaka...

1. A method for producing a disposable worn article including an around-torso member configured to cover a torso of a wearer and extend in a girth direction and an absorbent body configured to cover a crotch of the wearer, the method comprising the steps of:applying an adhesive on an elastic member extending in a carrying direction;
sandwiching the elastic member between two sheets of continuous non-woven fabric having a pair of side edge portions extending in the carrying direction, and bonding together the two sheets of continuous non-woven fabric along a part of a middle portion between the pair of side edge portions via the adhesive applied on the elastic member so that the two sheets of continuous non-woven fabric are laid on each other, thereby producing a continuous member; and
thermally welding together the two sheets of continuous non-woven fabric along the pair of side edge portions, which are closer to edges of the continuous member than the middle portion bonded by the adhesive, wherein:
the sandwiching step further comprises forming an unbonded central region without adhesive, the central region extending in the carrying direction and dividing the middle portion in two, and
the thermally welding step further comprises thermally welding the two sheets of continuous non-woven fabric together along the central region,
the method further comprises:
a step of cutting and dividing the continuous member, after the thermally welding step, along a virtual cutting line extending in the carrying direction in the central region into a first divided non-woven fabric and a second divided non-woven fabric;
a step of changing a positional relationship between the first and the second divided non-woven fabrics in a width direction perpendicular to the carrying direction by moving the first and the second divided non-woven fabrics relative to each other in the width direction so that the first and the second divided non-woven fabrics are spaced apart from each other in the width direction;
a step of placing absorbent bodies, after the changing step, so that each of the absorbent bodies bridges between the first and the second divided non-woven fabrics and so that each of the absorbent bodies is laid on a portion of the first divided non-woven fabric and on a portion of the second divided non-woven fabric, while the first and the second divided non-woven fabrics are carried in parallel to each other in the carrying direction, thereby producing a continuous laminate; and
a step of cutting the continuous laminate, after the placing step, in the width direction between the absorbent bodies adjacent to each other so that the continuous laminate is cut into an individual disposable worn article, wherein
the step of changing the positional relationship between the first and the second divided non-woven fabrics is carried out by crossing the first and the second divided non-woven fabrics so that the pair of side edge portions are placed between a first cut edge of the first divided non-woven fabric along the cutting line and a second cut edge of the second divided non-woven fabric along the cutting line, thereby the pair of side edge portions being spaced apart from each other while opposing each other in the width direction.

US Pat. No. 10,335,322

ADHESIVE SUPPORT DEVICES AND METHODS OF MAKING AND USING THEM

LightSide MD, LLC, Los A...

1. A method of making an adhesive support device having a three-dimensional shape, the method comprising:placing a planar sheet of material between a first tool and a second tool, wherein the sheet of material extends in a first plane and wherein the material has an elastic modulus of greater than 0.4 GPa;
stamping the planar sheet of material between the first tool and the second tool to deform a portion of the material so that it forms a cavity portion extending out of the first plane;
securing an adhesive substrate to a base region extending in the first plane wherein the base region is a portion of the planar sheet peripheral to the cavity portion; and
laser cutting one or more walls of the cavity portion using a laser that is oriented perpendicular to the first plane.

US Pat. No. 10,335,321

BREATHABLE INTERFACE SYSTEM FOR TOPICAL REDUCED PRESSURE

KCI Licensing, Inc., San...

1. A dressing for treating tissue comprising:an elongate applicator having a first end with a first width and a second end having a second width less than a first width, the elongate applicator having an aperture in the first end;
a porous pad;
a fabric layer having a first end located adjacent the aperture between the porous pad and the elongate applicator, the fabric layer extending from the first end to the second end of the elongate applicator;
a drape sealed to the elongate applicator and substantially enclosing the porous pad and the fabric layer; and
wherein the fabric layer has a second end is adapted to receive a reduced pressure from a conduit.

US Pat. No. 10,335,320

REDUCED-PRESSURE DRESSINGS, SYSTEMS, AND METHODS FOR USE WITH LINEAR WOUNDS

KCI Licensing, Inc., San...

1. A dressing assembly for treating a linear wound, comprising:a dressing bolster having a first side and a second, inward-facing side;
a comfort layer having a first side and a second, inward-facing side, the first side of the comfort layer coupled to the second, inward-facing side of the dressing bolster;
a first sealing member covering the dressing bolster;
a second sealing member covering a portion of the second, inward-facing side of the dressing bolster and extending outward from the dressing bolster, wherein a portion of the first sealing member is coupled to the second sealing member by an attachment device; and
a sealing ring disposed on and directly coupled to at least a portion of the second, inward-facing side of the comfort layer.

US Pat. No. 10,335,319

METHOD AND APPARATUS FOR CLEANING ISTHMUS OF EUSTACHIAN TUBE

Acclarent, Inc., Irvine,...

1. A method for cleaning an isthmus of a Eustachian tube (ET) of a patient using an instrument, wherein the instrument comprises a proximal portion, a distal portion, and a shaft extending therebetween, wherein the instrument further comprises a treatment feature disposed at the distal portion, the method comprising:(a) directing the instrument into an oro-nasal cavity of the patient;
(b) advancing at least the distal portion of the instrument into an opening of the ET;
(c) further advancing the instrument within the ET so that the treatment feature is disposed past, or is coincident with, the isthmus; and
(d) moving the treatment feature relative to the isthmus while atraumatically frictionally engaging the isthmus to thereby clean the isthmus by removing debris without damaging the isthmus.

US Pat. No. 10,335,318

LIGHT BLOCKING EYE COVER ATTACHABLE TO A PILLOW

1. An eye covering, comprising in combination:an elongate flexible sleeve having a hollow interior;
said sleeve flexible enough to be configured to wrap around a majority of a head of a wearer and against the head of the wearer;
said sleeve having an elongate form between a proximal end and a distal end;
said distal end and said proximal end free from coupling to other structures; and
said interior at least partially filled with a plurality of individual beads of media.

US Pat. No. 10,335,317

EYEWEAR HAVING MULTIPLE VENTILATION STATES

Oakley, Inc., Foothill R...

1. An assembly for attachment to an eyewear having a lens, the assembly being configured to transition between at least a first configuration and a second configuration, the assembly comprising:a subframe having a nose portion, wherein the subframe is configured to be positioned further apart from the lens in the second configuration than in the first configuration; and
an arm connected to the subframe, the arm configured to move between a first arm position in the first configuration and a second arm position in the second configuration, wherein moving the arm from the first arm position to the second arm position causes the assembly to transition from the first configuration to the second configuration;
wherein the assembly is configured to provide a low ventilation state in the first configuration with the subframe and the lens positioned closer together;
wherein the assembly is configured to provide a high ventilation state in the second configuration with the subframe and the lens positioned further apart from each other;
wherein the high ventilation state is configured to allow more ventilation between an eyewear and the face of the wearer than the low ventilation state.

US Pat. No. 10,335,316

CAPSULAR MEMBRANE TREATMENTS TO INCREASE ACCOMMODATIVE AMPLITUDE

1. An apparatus to treat an eye, the eye having a lens comprising a capsule, the apparatus comprising:a delivery device configured to be coupled to an intermediate portion of the capsule to deliver one or more of an energy or a substance to the intermediate portion of the capsule to stiffen the intermediate portion of the capsule; and
circuitry coupled to the delivery device to deliver the one or more of the energy or the substance to the eye to stiffen the intermediate portion of the capsule.

US Pat. No. 10,335,315

BI-RADIAL PATIENT INTERFACE

ALCON LENSX, INC.

1. A patient interface for an ophthalmic system, comprising:an attachment portion, configured to attach the patient interface to a distal end of the ophthalmic system;
a contact portion, configured for docking the patient interface to an eye; and
a contact element, coupled to the contact portion, comprising a pre-formed shape that includes, prior to contact with a surface of a cornea of the eye as part of the docking of the patient interface to the eye:
a transparent central portion with a central radius of curvature Rc,
a transparent peripheral portion with a peripheral radius of curvature Rp, wherein Rc is smaller than Rp, and
an edge structure where the transparent central portion and the transparent peripheral portion are joined, the edge structure configured to laterally stretch a central-cornea of the eye during the docking, the edge structure having a central diameter Dc in the range of 6-12 mm.

US Pat. No. 10,335,314

DELIVERY SYSTEM AND METHOD OF USE FOR THE EYE

IVANTIS, INC., Irvine, C...

1. An apparatus comprising:an inserter device comprising an interior space and a shaft disposed in the interior space; and
an intraocular implant adapted to self-retain to an inner wall of Schlemm's canal, the intraocular implant being disposed in the interior space of the inserter device, the intraocular implant comprising:
a proximal portion sized and shaped to reside within an anterior chamber of the eye, the proximal portion comprising a proximal opening;
a distal portion sized and shaped to reside within Schlemm's canal of the eye, the distal portion comprising a distal opening and a surface facing the proximal opening and configured to engage an inner wall of Schlemm's canal; and
a passageway extending in a straight line from the proximal opening to the distal opening to conduct fluid from the anterior chamber to Schlemm's canal,
the shaft being adapted to advance the intraocular implant out of the interior space and through an inner wall of Schlemm's canal.

US Pat. No. 10,335,313

METHOD FOR REMOVING COLORED SPOTS TO WHITEN THE EYE

1. A method for whitening an eye by removing pigmented lesions, nevi, and colored spots from the conjunctiva of the eye, comprising the steps of:topically applying an anesthetic to the eye;
preparing the ocular surface with a disinfectant;
inserting an eyelid speculum;
selecting an area of the conjunctiva to be removed, including a colored portion;
selecting and activating a motorized conjunctiva remover, which includes a body and an eye attachment with a tip, and which has a long axis along the length of the conjunctiva remover;
applying the tip of the eye attachment to the selected area of the conjunctiva to continuously wear away the conjunctiva until it is cleared of the colored portion;
deactivating the conjunctiva remover;
removing the eyelid speculum; and,
topically administering an antibiotic substance and an anti-inflammatory substance.

US Pat. No. 10,335,312

VAGINAL RING REMOVAL DEVICE AND METHODS

1. A device for removing an intravaginal drug delivery ring, the device comprising:an integral one-piece finger cot and a substantially rigid hook configured to remove said ring without injuring a vaginal cavity;
wherein said finger cot includes a finger opening, a closed end, a compression band, and an expandable sleeve;
wherein said hook extends away from said finger cot in a first direction and towards said finger cot in a second direction; and
wherein a distal end of said hook is aligned substantially parallel to a central axis of said finger opening and at an angle offset from said central axis.

US Pat. No. 10,335,311

ANTI-SNORING DEVICE

1. An anti-snoring device comprising:an elastic sheet including a first side, a second side, and an aperture, the second side including a first adhesive portion and a second adhesive portion; and
a tube including a first end, a second end, and a hollow interior, the first end of the tube disposed through the aperture of the elastic sheet, wherein the first end of the tube is coupled to the elastic sheet, such that the first end of the tube terminates at the first side of the elastic sheet and the second end of the tube extends a predetermined distance from the second side of the elastic sheet,
wherein, the second side of the elastic sheet is configured to be coupled to a user's face such that the first adhesive portion adheres to skin of the user below the user's nose and above the user's upper lip, the second adhesive portion adheres to the skin of the user below the user's lower lip, and the second end of the tube extends between the user's upper lip and lower lip into the interior of the user's mouth, the predetermined distance selected such that a portion of the upper lip is parted from a portion of the lower lip and the portion of the upper lip and the portion of the lower lip are prevented from touching while the second end of the tube is disposed in the interior of the user's mouth,
wherein, when the second side of the elastic sheet is coupled to the user's face, the elastic sheet is configured to draw the user's lower jaw toward the user's upper jaw to prevent the user from snoring while sleeping and the tube is configured with a predetermined outer circumference that enables the user's upper and lower lips to achieve a substantially closed position around the outer circumference of the tube and enables the user to breathe via the hollow interior of the tube.

US Pat. No. 10,335,310

APPARATUSES AND METHODS FOR DISRUPTING AND PREVENTING SNORE

1. An apparatus for disrupting or preventing snoring, the apparatus comprising:a bladder assembly comprising a sleeve assembly and an inflatable bladder configured to be received within the sleeve assembly, wherein the sleeve assembly comprises a plurality of rigid segments, each rigid segment being pivotally hinged to an adjacent rigid segment;
the inflatable bladder configured to:
inflate to expand the plurality of rigid segments outwardly along a longitudinal axis of the bladder assembly to raise an entire top surface of the bladder assembly substantially in parallel; and
deflate to lower the entire top surface of the bladder assembly substantially in parallel;
wherein a total time of inflation and deflation comprises one inflation cycle;
a conduit connecting the inflatable bladder to an air inflator, the air inflator for inflating the inflatable bladder;
a controller in communication with the air inflator, the controller configured to actuate the air inflator;
suspension components to suspend the air inflator inside a soundproof housing; and
an audio processor in communication with the controller, the audio processor being configured to detect sound waves including a snoring sound, and transmit control commands to the controller to actuate the air inflator to initiate the one inflation cycle once a trigger event is detected.

US Pat. No. 10,335,309

ADAPTABLE OSTOMY BASE PLATE

1. An ostomy base plate attachable around a stoma of a user and provided to allow a waste collecting bag to be attached to and removed from the ostomy base plate, the ostomy base plate comprising:a wafer having a hole adapted to be placed around the stoma of the user, and a distal side opposite of a proximal side, with the proximal side of the wafer including an adhesive that extends from an adhesive region around the hole to an outermost perimeter of the wafer, where the adhesive is adapted to secure the proximal side of the wafer to skin of the user around the stoma;
a coupling device provided on the distal side of the wafer and adapted to couple with the waste collecting bag, the coupling device surrounding the hole in the wafer; and
a connecting element having an inner periphery connected to the coupling device and an outer periphery connected to the distal side of the wafer;
wherein the connecting element extends away from the distal side of the wafer to separate a proximal side of the coupling device an offset distance away from the distal side of the wafer;
wherein the proximal side of the wafer is convex such that:
a) the adhesive region around the hole contacts the skin of the user when the hole is placed around the stoma of the user, and
b) the outermost perimeter of the wafer is located distal to a distal end of the coupling device to space the outermost perimeter of the wafer away from the skin of the user.

US Pat. No. 10,335,308

FLEXIBLE BARRIER FILMS CONTAINING CYCLIC OLEFINS

Avery Dennison Corporatio...

34. A method for reducing transmission of odorous species, the method comprising:providing at least one layer including a blend of cyclic olefin copolymers (COC), wherein the blend includes a semi-crystalline COC and a norbornene COC, wherein a total norbornene concentration of the norbornene COC in the at least one layer is from about 12% to about 60% by mole based upon the total moles of COCs in the layer;
forming a barrier film including the at least one layer including a blend of cyclic olefin copolymers (COC); and
positioning the barrier film between a source of odorous species and a user;
wherein the semi-crystalline cyclic olefin copolymer has a glass transition temperature of from about ?20° C. to about 20° C.

US Pat. No. 10,335,307

PENILE CONSTRICTION DEVICE

OVO JOINT VENTURE LLC, H...

1. A penile constriction device comprising:a ring-shaped body and an elongated head element having a length that is greater than its maximum width, wherein the head element extends lengthwise in a radial direction relative to the ring-shaped body;
wherein the ring-shaped body has an interior diameter sized to closely encircle a penis, and the head element is removably attached to the ring-shaped body; and
wherein the head element is disposed so that the head element can contact a clitoris during sexual intercourse when the ring-shaped body is positioned on the penis;
wherein the ring-shaped body has an outer peripheral portion at which the head element is provided;
wherein the head element extends in an essentially radial direction relative to the ring-shaped body;
wherein the ring-shaped body is provided with a coupling means for removably mounting the head element to the ring-shaped body; and
wherein the coupling means comprises a protruding portion extending away from the ring-shaped body and wherein the head element includes an opening adapted to accommodate the protruding portion.

US Pat. No. 10,335,306

SUPPORTER

KOWA CO., LTD, (JP) ADVA...

1. A supporter formed of a band-shaped member, the supporter comprising:a back-contact section that is arranged substantially at the center of the band-shaped member, and that is adapted to come in contact with a wearer's back region;
protruding sections that are arranged at both sides of the back-contact section;
a pair of auxiliary band sections that defines two band-shaped members having stretchability in a longitudinal direction and in which an annular ring is arranged to be slidable over each band-shaped member; and
a pair of adjustment band sections that defines two band-shaped members having stretchability lower than the stretchability of the auxiliary band sections,
wherein each protruding section includes a stretchable portion being in contact with the back-contact section and having stretchability in the longitudinal direction and a non-stretchable portion having no stretchability,
wherein both ends of the pair of auxiliary band sections are fixed so that the two band-shaped members cross each other on the back-contact section,
wherein each of the pair of adjustment band sections is slideably inserted into the annular rings arranged in the auxiliary band sections, and
wherein the pair of adjustment band sections includes:
a first adjustment band section in which one end of the band-shaped member is fixed to the non-stretchable portion of the right protruding section and an other end of the band-shaped member is able to be fastened to the non-stretchable portion of the right protruding section, and
a second adjustment band section in which one end of the band-shaped member is fixed to the non-stretchable portion of the left protruding section and an other end of the band-shaped member is able to be fastened to the non-stretchable portion of the left protruding section.

US Pat. No. 10,335,305

SELF-ACTIVATED LIFTING VEST WITH SENSORY-FEEDBACK AND METHODS OF USE THEREOF

Strong Arm Technologies, ...

1. A support device comprising:a garment configured to be worn by a user, the garment including a back plate having an upper portion and a lower portion, the back plate configured and positioned to extend vertically along a central portion of a back of the user such that the upper portion of the back plate is proximate to an upper central portion of the back and the lower central portion of the back plate is proximate to a lower portion of the back when the garment is worn by the user;
a pivot point located at the upper portion of the back plate; and
at least one sensory feedback element coupled to the lower portion of the back plate, the at least one sensory feedback element configured to press into the back of the user in response to a non-ergonomic lifting posture by the user during a lifting operation, wherein the non-ergonomic lifting posture includes bending at the waist with a hunched back.

US Pat. No. 10,335,304

PRESSING TOOL FOR PELVIC FLOOR MUSCLE GROUP

1. A pressing tool adapted for use with a pelvic floor muscle group of a human body comprising:a pressing tool main body having a length in a longitudinal direction adapted to be at least as long as a length between a pubis and a coccyx and having a width in a width direction with respect to the longitudinal direction that is adapted to be shorter than a length between an ischia, as a pair,
wherein a part of the pressing tool main body in the longitudinal direction is configured to be at least as long as the length between the pubis and the coccyx has a convex upper surface formed in a convex shape headed outward from the pressing tool main body,
wherein a convex lower surface is provided at a position opposed to the convex upper surface and the convex lower surface is formed in an arc having a curvature larger than the convex upper surface,
wherein the pressing tool for a pelvic floor muscle group is mounted to have a positional relationship in which the longitudinal direction corresponds to a front-back direction so that the convex upper surface may be located highest in the pressing tool main body and so that the longitudinal direction of the pressing tool main body may be along a seat surface, and the pressing tool is configured such that when the human body sits on the seat surface and mounts the convex upper surface, the convex upper surface is adapted to oppose the pubis and the coccyx,
wherein, as for the pressing tool main body, the convex upper surface has a hardness of 10 to 20, which is a value of the International Rubber Hardness Degree (IRHD) complying with JIS K 6253, when the pressing tool main body is in an initial state in which the pressing tool main body is subject to no external force and is not squashed, and has a hardness of 25 to 35, which is a value of the International Rubber Hardness Degree (IRHD) complying with JIS K 6253, when the pressing tool main body is subject to being squashed during use, and a height from the seat surface to the convex upper surface becomes a half of the height from the seat surface to the convex upper surface in the initial state, and
wherein the pressing tool main body has a hard portion made of a urethane resin and a soft portion made of a urethane resin.

US Pat. No. 10,335,303

INTRAGASTRIC DEVICE

Obalon Therapeutics, Inc....

1. A device for assisting a patient in swallowing an intragastric balloon, comprising:an elongate tube comprising a body and an elongate slit, the body having a through-bore extending from a first orifice of the elongate tube to a second orifice of the elongate tube, wherein the elongate slit extends through the body from the first orifice to the second orifice;
a gastric balloon assembly reversibly attached to the second orifice, the gastric balloon assembly comprising an inflation catheter engaged with a gastric balloon in a capsule and extending out of the first orifice, wherein the elongate slit is sized and shaped for the inflation catheter to pass therethrough, and wherein the gastric balloon assembly is attached to the first orifice by a press-fit;
a handle member; and
an engagement subassembly comprising a female portion and a male portion, wherein the engagement subassembly is configured and arranged for threading the inflation catheter into and engaging the elongate tube.

US Pat. No. 10,335,302

SYSTEMS AND METHODS FOR USING TRANSCUTANEOUS ELECTRICAL STIMULATION TO ENABLE DIETARY INTERVENTIONS

Elira, Inc., St. Louis, ...

1. A system to generate real-time interventions in response to a patient's degree of appetite, comprising:an electrical dermal patch comprising:
a housing;
a controller positioned within the housing;
at least one electrode positioned in physical communication with the housing and adapted to be in electrical contact with the patient's skin; and,
a pulse generator positioned within the housing and in electrical communication with the controller and said at least one electrode, wherein the pulse generator is configured to generate a plurality of stimulation sessions comprising a plurality of electrical pulses defined by stimulation parameters and wherein said stimulation parameters comprise a first pulse width in a range of 10 ?sec to 10 msec, a first pulse amplitude in a range of 100 ?A to 100 mA, and a first pulse frequency in a range of 1 Hz and 100 Hz;
a first plurality of programmatic instructions stored in a non-transient memory in a client device separate from the electrical dermal patch, wherein, when executed, said first plurality of programmatic instructions is adapted to cause the client device to generate a prompt to the patient to input data indicative of the patient's degree of appetite via a microphone or a display of said client device;
a second plurality of programmatic instructions stored in a non-transient memory in the client device or another device separate from the electrical dermal patch, wherein, when executed, said second plurality of programmatic instructions determines an appetite pattern of the patient based upon said inputted data; and
a third plurality of programmatic instructions stored in a non-transient memory in the client device or another device separate from the electrical dermal patch, wherein, when executed, said third plurality of programmatic instructions determines an intervention and generates said intervention based on the appetite pattern.

US Pat. No. 10,335,301

MODULAR HANDLE COMPRISING A TRIGGER WIRE ACTUATION MECHANISM FOR A PROSTHESIS DELIVERY DEVICE

Cook Medical Technologies...

1. A handle assembly for a prosthesis delivery device comprising:a stationary main handle having a proximal end and a distal end and an outer surface extending therebetween;
a first helical groove formed in at least a portion of the outer surface of the main handle;
a first trigger wire actuation mechanism disposed about the main handle and rotatably moveable relative to the main handle;
a first trigger wire operatively connected to the first trigger wire actuation mechanism, the first trigger wire having a prosthesis capture condition and a prosthesis release condition;
wherein movement of the first trigger wire actuation mechanism causes movement of the first trigger wire thereby moving the first trigger wire from the prosthesis capture condition to the prosthesis release condition; and
a first ratcheting mechanism that permits rotation of the first trigger wire actuation mechanism in a first direction and prevents rotation of the first trigger wire actuation mechanism in a second direction, wherein the first ratcheting mechanism is a ratchet ring disposed between the outer surface of the main handle and an inner surface of the first trigger wire actuation mechanism.

US Pat. No. 10,335,300

SYSTEM FOR DEPLOYING A CAPACITIVE SHAPE MEMORY CATHETERIZATION DEVICE AND METHODS FOR USE THEREWITH

Memory Effect Medical, LL...

1. A system for deploying a shape memory catheterization device within a patient, the system comprising: a shape memory polymer that includes a plurality of conductive plates, wherein the shape memory polymer has a transition temperature that is higher than a normal body temperature of the patient; a catheter having a delivery rod for endovascular insertion of the shape memory polymer; a heat source for heating the shape memory polymer above the transition temperature, wherein the heat source utilizes a microwave source that is separate from the shape memory polymer, wherein heating the shape memory polymer above the transition temperature causes the shape memory polymer to undergo a shape transformation from a catheterization shape to a transformed shape, and further causes a change in a capacitance of the shape memory polymer as a result of the shape transformation; a transformation data generator, coupled to the catheter, that includes a power source for driving a detection circuit that monitors the change in the capacitance of the shape memory polymer based on monitoring at least one of: a charging time or a discharging time of the plurality of conductive plates of the shape memory polymer, and generates transformation data based on the change in the capacitance of the shape memory polymer resulting from the shape transformation of the shape memory polymer; a heating control generator that utilizes a processing device and memory to generate a control signal for controlling the microwave source based on the transformation data, wherein the heating control generator generates the control signal to discontinue the heating of the shape memory polymer by the microwave source when the transformation data indicates the shape transformation of the shape memory polymer from the catheterization shape to the transformed shape; and wherein the delivery rod includes a plurality of electrodes that are electrically coupled to a portion of the shape memory polymer to detect the change in capacitance of the shape memory polymer, wherein the delivery rod is removed from the patient in response to the transformation data indicating the shape transformation of the shape memory polymer from the catheterization shape to the transformed shape, and wherein the plurality of electrodes are decoupled from the shape memory polymer to enable removal of the delivery rod from the body of the patient while allowing the shape memory polymer to remain in the body of the patient.

US Pat. No. 10,335,299

VESSEL PROSTHESIS

Terumo Corporation, Toky...

1. A vascular prosthesis comprising:a plurality of wires woven together to form a tubular shape with a plurality of loops on each end of the tubular shape; said plurality of loops being arranged in an alternating pattern of longer loops and shorter loops;
each of said plurality of loops terminating with a cap having a cylindrical body and a rounded distal end; said cap comprising a trimmed first wire end, a trimmed second wire end, and a metal tube positioned flush over and melted together with said trimmed first wire end and said trimmed second wire end.

US Pat. No. 10,335,298

STENT

1. A stent having a distal end and a proximal end and a longitudinal axis, the stent comprising:a first circumferential row arranged near the proximal end and extending substantially perpendicular to the longitudinal axis;
a second circumferential row arranged near the distal end and extending substantially perpendicular to the longitudinal axis;
a plurality of struts configured to longitudinally stabilize the stent; and
an intermediate section extending at an angle relative to the longitudinal axis and being axially interposed between and directly connected to the first circumferential row and the second circumferential row, the intermediate section having uniform apex angles and uniform apex amplitude along a length thereof to form a uniform apex geometry the stent having an insertion configuration and a deployed configuration, the stent configured to maintain a length that is substantially constant as the stent transforms from the insertion configuration to the deployed configuration.

US Pat. No. 10,335,297

STENT AND STENT DELIVERY DEVICE

Terumo Corporation, Toky...

1. An implant device comprising:a first tubular layer having a first porosity and being woven from at least one wire composed of a shape memory metal; and,
a second tubular layer having a second porosity and being woven from at least one wire composed of a shape memory metal; said second tubular layer being located in said first tubular layer; and,
a connecting member woven through both said first tubular layer and said second tubular layer;
wherein said first tubular layer and said second tubular layer have substantially the same pitch and substantially no clearance between the layers.

US Pat. No. 10,335,295

LINER FOR A PROSTHESIS CONFIGURED TO EVACUATE A VOLUME BETWEEN THE LINER AND A SOCKET USING A VALVE AND PUMP CHAMBER EACH POSITIONED WITHIN THE LINER

1. A liner for a prosthesis, comprising:an inner face;
an outer face;
at least one flow channel having at least one inlet opening and at least one outlet opening, the at least one flow channel extending between the inner face and the outer face;
a one-way valve arranged in the at least one flow channel in such a manner that a medium can flow through the one-way valve only from the at least one inlet opening to the at least one outlet opening, the one-way valve being configured to evacuate a volume between a distal end of the liner and a prosthesis socket of the prosthesis.

US Pat. No. 10,335,294

SYSTEMS AND METHODS FOR AUTOMATICALLY TUNING POWERED PROSTHESIS IMPEDANCE CONTROL PARAMETERS

North Carolina State Univ...

1. A system for tuning powered prosthesis impedance control parameters, comprising:a powered prosthesis comprising:
a joint,
a motor mechanically coupled to the joint, the motor being configured to drive the joint,
a plurality of sensors configured to measure a plurality of gait parameters associated with a subject, and
an impedance controller configured to output a control signal for adjusting a torque of the motor;
an intelligent tuner operably connected to the powered prosthesis, wherein the intelligent tuner is configured to implement an intelligent computing algorithm for adjusting at least one of a plurality of impedance control parameters using a rule base, and wherein the rule base encodes human expert decision making using a plurality of rules that link changes in the measured gait parameters to corresponding adjustments to the impedance control parameters; and
a finite state machine operably connected to the powered prosthesis, wherein the finite state machine is configured to determine a gait cycle state based on the measured gait parameters and select a set of adjusted impedance control parameters based on the gait cycle state, wherein the impedance controller is configured to adjust the torque of the motor as a function of the measured gait parameters and the set of adjusted impedance control parameters.

US Pat. No. 10,335,293

DAMPING CONTROL METHOD FOR LOWER-LIMB PROSTHESES

PEKING UNIVERSITY, Shenz...

1. A damping control method for a lower-limb prosthesis, comprising the following steps:isolating a driving motor of the lower-limb prosthesis from a driving voltage, and operating the driving motor as a generator,
wherein the generator generates an alternating induced voltage from a joint rotation resulting from locomotion of a human body's CoM (Center of Mass), and where the method further comprises:
transforming the alternating induced voltage to a direct-current voltage with a full-bridge rectification circuit made of Schottky diodes or ideal diodes;
connecting output terminals of the full-bridge rectification circuit with a controlled switch to form a closed circuit, and generating induced current from the direct-current voltage; and
controlling the on-off ratio of the controlled switch with a Pulse-Width-Modulation (PWM) signal to generate a controllable motor current that results in a controllable braking torque under the magnetic field of the driving motor.

US Pat. No. 10,335,292

TORQUE MEASURING SPRING FOR A PROSTHETIC DEVICE

Bionx Medical Technologie...

1. An apparatus comprising:a first member;
a second member moveably connected to the first member;
a spring member fixed to the first member, the second member contacting the spring member during at least a portion of the movement of the second member with respect to the first member, the spring member deflecting from a neutral position when contacted by the second member and providing resistance to the rotation of the second member; and
a contact plate, attached to the spring member at the point of contact between the spring member and the second member.

US Pat. No. 10,335,291

HYDRAULIC SYSTEM FOR A KNEE-ANKLE ASSEMBLY CONTROLLED BY A MICROPROCESSOR

PROTEOR, Saint-Apollinai...

1. A femoral knee-ankle prosthesis comprising:a femoral segment suitable for a femoral connection to a user and a tibial segment connected to the femoral segment based on an articulation which reproduces the movements of the knee, the tibial segment being articulated on one foot based on an articulation reproducing the movements of the ankle, a first hydraulic cylinder of which the ends are joined respectively with the femoral and tibial segments, and a second hydraulic cylinder of which the ends are joined respectively with the tibial segment and the foot, an upper chamber of the first hydraulic cylinder is connected to a lower chamber of the second hydraulic cylinder through a conduit connected laterally to the upper chamber of the first hydraulic cylinder, and an electronic control unit that controls both of the first hydraulic cylinder and the second hydraulic cylinder depending on the phase of the walking cycle and a situation faced by the user including a stance phase and a swing phase in such a manner that a first flexion of the knee allows a first dorsiflexion of the ankle in proportion to the movement of the knee during the stance phase and such that a second flexion of the knee results in a second dorsiflexion of the ankle in proportion to the movement of the knee during the swing phase.

US Pat. No. 10,335,290

EXPANDABLE INTERBODY FUSION DEVICE

SPINE WAVE, INC., Shelto...

1. An expansion member for use in an expandable interbody fusion device for implantation into the intradiscal space between opposing vertebral bodies in a spine, comprising:a unitary elongate body including a leading distal end, a trailing proximal end, and opposed lateral edges therebetween defining a maximum width, said body being sized and configured to move within an expandable interbody fusion device and to cause expansion of said device upon such movement, said body having a first beveled surface inclining in a first direction and extending across said maximum width from one lateral edge to the other, said first beveled surface defining a lifting surface, said body including a second beveled surface inclining in said first direction spaced proximally axially from said first beveled surface, said body including a locking surface and a bone filler facilitator selected from the group of facilitators consisting of tunnels, grooves and holes for receipt therein of a bone filler.

US Pat. No. 10,335,289

STAND ALONE INTERVERTEBRAL FUSION DEVICE

DePuy Synthes Products, I...

1. An intervertebral fusion device comprising:i) an intervertebral cage including;
a) upper and lower surfaces that are spaced from each other along a first direction and are configured to engage respective vertebral bodies;
b) a proximal wall that defines a proximal surface;
c) a distal wall opposite the proximal wall, and
d) first and second side walls connected between the proximal and distal walls, wherein the proximal surface defines a center that is equidistantly spaced from the first and second side walls; and
ii) a plate that defines a through-hole extending therethrough, wherein the plate is slidable along the proximal surface of the intervertebral cage along a direction of sliding that lies in a plane that is perpendicular to the first direction; and
iii) a screw received by the through-hole of the plate,
wherein the intervertebral cage defines a hole that extends into the proximal wall, and when the screw extends into the hole of the intervertebral cage, the plate is configured to be disposed in a position whereby 1) the through-hole of the plate is offset in its entirety from the center along the plane so as to define a gap between the through-hole and the center along the plane, 2) a first portion of the hole is aligned with the through-hole of the plate, and 3) a second portion of the hole is offset from the through-hole of the plate along the plane, the second portion of the hole being different than the first portion of the hole,
wherein the plane extends through both the through-hole of the plate and a central location of the hole of the intervertebral cage, the central location of the hole being centrally disposed in the hole with respect to the first direction.

US Pat. No. 10,335,287

SPINAL FUSION IMPLANT AND RELATED METHODS

NuVasive, Inc., San Dieg...

1. An implant comprising:a body having a top surface and a bottom surface, a first sidewall and a second sidewall opposing one another, the first sidewall having a first length and the second side wall having a second length, and a first end and a second end, the first sidewall joining the upper surface at a first corner extending along a length of the body a first corner length and joining the bottom surface at a second corner extending along a length of the body a second corner length, the second sidewall joining the upper surface at a third corner extending along a length of the body a third corner length and joining the bottom surface at a fourth corner extending along a length of the body a fourth corner length, each of the first, second, third, and fourth corners being rounded, the second corner having a second corner radius that is constant along the second corner length and the third corner having a third corner radius that is constant along the third corner length, the first corner having a first corner radius that is variable along the first corner length and the fourth corner having a fourth corner radius that is variable along the fourth corner length, wherein the first corner length and the second corner length are equal to the first length of the first sidewall and the third corner length and the fourth corner length are equal to the second length of the second sidewall.

US Pat. No. 10,335,286

EXPANDABLE INTERSPINOUS PROCESS SPACER IMPLANT

DePuy Synthes Products, I...

1. A method of implanting an expandable spacer implant into a vertebral space defined between a superior vertebral body and an inferior vertebral body that are spaced from one another along a first direction, the method comprising:inserting the implant into the vertebral space in a collapsed configuration such that (i) an outer surface of a first housing of the implant engages one of the superior and inferior vertebral bodies, (ii) an outer surface of a second housing of the implant engages another of the superior and inferior vertebral bodies, (iii) inner surfaces of the first and second housings face one another and are spaced from the outer surfaces of the first and second housings along the first direction, (iv) the first and second housings extend from a proximal-most end of the implant to a distal-most end of the implant along a second direction, perpendicular to the first direction; and (v) a first pair of internal surfaces of the second housing are spaced from one another along the second direction and a second pair of internal surfaces of the second housing are spaced from one another along a third direction, perpendicular to the first and second directions, so as to at least partially define a void that extends into the inner surface of the second housing; and
expanding the implant by rotating a distracting member about an axis of rotation that extends along the second direction so as to move the distracting member within the void from a first position, wherein a first pair of opposed surfaces of the distracting member that define a first distance therebetween engage the first and second housings, to a second position, wherein a second pair of opposed surfaces of the distracting member that are angularly offset with respect to the first pair of opposed surfaces of the distracting member and define a second distance therebetween, greater than the first distance, engage the first and second housings so as to cause the first and second housings to move away from one another along the first direction, wherein the expanding step comprises causing a stabilizer to protrude beyond the outer surface of at least one of the first and second housings when the first and second housings are moved away from one another.

US Pat. No. 10,335,285

REVISEABLE STEMLESS PROSTHESES AND METHODS

Howmedica Osteonics Corp....

1. An orthopedic revision system comprising:a base member having a collar portion and at least one stabilization portion extending distally from the collar portion; and
a stem member having an attachment portion and a shaft portion,
wherein the stem member is configured to be received at least partially through an opening in the collar portion such that the attachment portion lies adjacent the collar portion and the shaft portion lies adjacent the at least one stabilizing portion.

US Pat. No. 10,335,284

TIBIAL IMPLANT HAVING AN ANATOMIC STEM

1. A tibial implant, comprising:a tray configured to abut a patient's bone; and
a stem extending distally from a surface of the tray and configured to extend longitudinally through a tibial intramedullary cavity of the patient's bone to a distal tip of the tibial implant, said stem having:
a proximal portion at a proximal level relative to the tray at which the stem has a proximal shape and a first center; and
a distal portion at a distal level relative to the tray at which the stem has a distal shape and a second center;
wherein the proximal shape and the distal shape comprise at least a first rounded corner, a second rounded corner, and a third rounded corner, the first and second rounded corners being adjoined by a first side, the second and third rounded corners being adjoined by a second side, and the third and first rounded corners separated by at least a third side;
wherein a first distance from the first center to the first rounded corner at the proximal level is greater than a second distance from the first center to the first side at the proximal level to provide anti-rotation contact between the first rounded corner at the proximal level and a bone near to which the first side at the proximal level is to be implanted; and
wherein, between at least the proximal portion and the distal portion of the stem, the second rounded corner shifts laterally relative to a longitudinal axis of the stem in a lateral direction away from the first center point.

US Pat. No. 10,335,283

REVERSE HIP SYSTEM AND METHOD

1. A reverse hip prosthesis comprising:an acetabular cup anchor portion configured for insertion into an acetabulum of a patient and fixation therein, the acetabular cup anchor portion including a convex surface for engagement with the patient's acetabulum and a concave surface opposite to the convex surface;
a plurality of first wearable inserts which are different from each other, and each of which may be selectively fixed to the acetabular cup anchor portion such that the first insert covers the concave surface of the acetabular cup anchor portion;
an acetabular stem having a first threaded end configured to be fixed to the acetabular cup anchor portion and/or the patient's acetabulum and a second threaded end extending in an opposite direction to the first threaded end;
an acetabular ball having a threaded recess therein which is attached to the second threaded end the acetabular stem;
a femoral stem configured for insertion into an intramedullary femoral canal of the patient;
a femoral cup attached to the femoral stem and having a concave surface which partially surrounds the acetabular ball; and
a second wearable insert which is fixed to the femoral cup and covers the concave surface of the femoral cup;
wherein the acetabular cup anchor portion is a largest size suitable for the patient's acetabulum, and the acetabular stem also functions as an artificial ligamentum teres.

US Pat. No. 10,335,282

MAGNETIC JOINT REPLACEMENT

Richard A. Rogachefsky, ...

1. A hip joint prosthesis, comprising:a femoral head comprising a plurality of magnets positioned on an anterior surface of the femoral head, the plurality of magnets comprising a first femoral magnet and a second femoral magnet, the first femoral magnet configured to provide a stronger magnetic field than the second femoral magnet;
an acetabular cup corresponding to the femoral head, the acetabular cup comprising a second plurality of magnets positioned on a posterior surface of the acetabular cup, the second plurality of magnets comprising a first acetabular cup magnet and a second acetabular cup magnet, the first acetabular cup magnet configured to provide a stronger magnetic field than the second acetabular cup magnet;
wherein the femoral head is configured to rotate within the acetabular cup through a range of motion corresponding to about 0-120 degrees of hip flexion, the first femoral magnet positioned on a medial side of the anterior surface of the femoral head and the first acetabular cup magnet positioned on a lateral side of the posterior surface of the acetabular cup such that the first femoral magnet and the first acetabular cup magnet align to form the strongest magnetic force between the first femoral magnet and the first acetabular cup magnet when the femoral head is in a position corresponding to about 90-120 degrees of hip flexion.

US Pat. No. 10,335,281

CARTILAGE MOSAIC COMPOSITIONS AND METHODS

ALLOSOURCE, Centennial, ...

1. A mosaic cartilage composition comprising:a 1 mm thick cartilage sheet comprising a plurality of interconnected cartilage tiles that are separated by channels formed in the cartilage sheet, each channel having a respective depth that is less than 1 mm, and wherein perforations are formed in the cartilage sheet beneath one or more of the channels; and
a cryopreservation medium.

US Pat. No. 10,335,280

METHOD FOR ABLATING TARGET TISSUE OF A PATIENT

Medtronic, Inc., Minneap...

1. A method for treating a human patient, the method comprising:emitting ultrasound energy from an ultrasound transducer positioned remotely from target tissue of the patient, wherein the ultrasound transducer is positioned at a desired location relative to the patient and target tissue using location and imaging techniques;
focusing the ultrasound energy such that one or more focal points are directed to the target tissue of the patient; and
ablating the target tissue at each focal point with the focused ultrasound energy without ablating non-target tissue through which the ultrasound energy passes between the ultrasound transducer and the one or more focal points.

US Pat. No. 10,335,279

METHOD AND DEVICE FOR TREATING DYSFUNCTIONAL CARDIAC TISSUE

BioVentrix, Inc., San Ra...

1. A patch for reducing a volume of a ventricle of a heart chamber comprising:a main body that is positionable about dysfunctional tissue of the ventricle, the main body comprising a woven fabric material; and
a deformable slit that extends upward from the main body, the deformable slit comprising a malleable metal material, the deformable slit having a shape of an elongated ellipse and forming a continuous, closed loop configured to allow the dysfunctional tissue to be pulled through the loop, wherein:
the woven fabric material extends continuously around the loop;
opposing walls of the deformable slit are configured to be displaced inwardly after the dysfunctional tissue is pulled through the loop to secure the patch about the dysfunctional tissue and reduce the volume of the ventricle; and
the opposing walls of the deformable slit comprise a more parallel configuration after the opposing walls are displaced inwardly.

US Pat. No. 10,335,278

PROSTHETIC HEART VALVE DEVICES, PROSTHETIC MITRAL VALVES AND ASSOCIATED SYSTEMS AND METHODS

Twelve, Inc., Menlo Park...

1. A prosthetic heart valve device for treating a valve of a human heart having a native annulus and native leaflets, comprising:a valve support having an upstream region and a downstream region with respect to a direction of blood flow;
a prosthetic valve within the valve support; and
an anchoring member having a connection structure and a fixation portion, the connection structure being attached to the valve support in an undeployed state and at least a portion of the connection structure extending laterally outward with respect to the valve support in a deployed state, the fixation portion having a plurality of interconnected struts that define an annular engagement surface and that are spaced laterally apart and outward from the valve support by the connection structure in the deployed state, wherein
at least a portion of the connection structure extends transverse with respect to the direction of blood flow,
the fixation portion extends upstream with respect to the connection structure and generally along the direction of blood flow, and
the annular engagement surface anchors the device to the native annulus.

US Pat. No. 10,335,277

ADJUSTABLE NOSECONE

BOSTON SCIENTIFIC SCIMED ...

1. A percutaneous valve delivery system, comprising:an outer sheath;
an inner catheter disposed within the outer sheath, the inner catheter including a plurality of non-concentric lumens formed therein;
a tubular extension extending distally from a distal end of the inner catheter;
wherein the tubular extension is axially movable relative to the inner catheter;
wherein the tubular extension is fixedly attached to and within a hypotube slidably received within one of the plurality of lumens;
a nose cone attached to the tubular extension;
a handle attached to the outer sheath, wherein the handle is configured to shift the outer sheath between a first position and a second position relative to the inner catheter; and
a valve replacement implant releasably coupled to the inner catheter.

US Pat. No. 10,335,276

TAVR VENTRICULAR CATHETER

1. A method of positioning an x-ray C-arm in coplanar alignment with an aortic valve, the method comprising:advancing a guide wire into a patient's aorta, across the patients aortic valve annulus, and into the patient's left ventricle cavity;
advancing an undeployed catheter along the guide wire into the patient's aorta, across the patient's aortic valve annulus, and into the patient's left ventricle cavity;
retracting the guide wire until the undeployed catheter deploys to form a deployed catheter, the deployed catheter comprising
a distal ring, the distal ring comprising a radiopaque outer surface and a plurality of openings for dispersing contrast medium; and
a substantially straight upper shaft connecting to the distal ring via a plurality of curves, the upper shaft disposed substantially perpendicularly to the distal ring, the distal ring, the upper shaft and the plurality of curves all formed unitarily from a resilient hollow tube;
retracting the deployed catheter until the deployed catheter contacts the patient's aortic valve on the ventricular side of the aortic valve and on opposite sides of the aortic valve annulus, the upper shaft extends through the aortic valve and the distal ring is beneath the leaflets of the aortic valve;
injecting radio opaque fluid into the deployed catheter to confirm catheter position; and
positioning the C-arm using images of the distal ring.

US Pat. No. 10,335,275

METHODS FOR DELIVERY OF HEART VALVE DEVICES USING INTRAVASCULAR ULTRASOUND IMAGING

MILLIPEDE, INC., Santa R...

24. A method of delivering an implant proximate a cardiac valve annulus, the method comprising:advancing a distal end of a delivery catheter proximate the cardiac valve annulus;
advancing the implant through the distal end of the delivery catheter proximate the cardiac valve annulus;
advancing a distal end of an ultrasound catheter proximate the cardiac valve annulus, the distal end of the ultrasound catheter including one or more ultrasonic transducers;
capturing an ultrasound image of the implant and the cardiac valve annulus with the one or more ultrasonic transducers; and
anchoring the implant to the cardiac valve annulus,
wherein the implant is a cardiac valve replacement and comprises:
a series of struts defining a tubular frame and an axis and forming a plurality of lower crowns;
a plurality of anchors coupled with the lower crowns of the frame and configured to translate axially relative to the frame to engage cardiac tissue proximate the cardiac valve annulus; and
a plurality of valve leaflets coupled with the frame.

US Pat. No. 10,335,274

ERGONOMIC MITRAL HEART VALVE HOLDERS

Edwards Lifesciences Corp...

1. A combination including a holder for handling and delivering a prosthetic mitral heart valve to an implantation site, comprising:a prosthetic mitral heart valve having an inflow end and three flexible commissure posts ending in tips projecting in an outflow direction;
a holder body contacting the inflow end of the heart valve, the holder body defining a central window aligned along an inflow-outflow axis through which leaflets of the heart valve are visible and having at least one peripherally-extending internal passage extending around the central window, wherein the holder body has relatively rotatable rings; and
three connecting sutures each fixed to the holder body and having a loop extending at least partly around the peripherally-extending internal passage, out of the holder body and along each of the commissure posts of the heart valve, the three loops of the connecting sutures mutually crossing over between the tips of the commissure posts, wherein each connecting suture has two free ends attached to different rotatable rings of the holder body, and wherein relative rotation of the rings applies tension to the connecting suture loops and causes the commissure post tips to move radially inward.

US Pat. No. 10,335,273

LEAFLET ENGAGEMENT ELEMENTS AND METHODS FOR USE THEREOF

BOSTON SCIENTIFIC SCIMED ...

1. An apparatus for endovascularly replacing a patient's heart valve, the apparatus comprising:an expandable anchor supporting a replacement valve disposed within a lumen of the expandable anchor; and
a delivery catheter defining a lumen, the delivery catheter being adapted to deliver the expandable anchor and replacement valve to a vicinity of the patient's heart valve within the lumen in a collapsed configuration;
wherein the expandable anchor and replacement valve are adapted for percutaneous delivery and deployment to replace the patient's heart valve;
wherein the expandable anchor comprises a plurality of closed cells forming a body portion of the expandable anchor and a proximal flange portion of the expandable anchor in a deployed configuration, the proximal flange portion extending radially outward from the body portion in the deployed configuration;
wherein closed cells forming the proximal flange portion are larger than closed cells forming the body portion, wherein the expandable anchor and the replacement valve are further adapted to permit blood flow through the replacement valve and to prevent blood backflow through the replacement valve after the replacement valve exits the delivery catheter and before the proximal flange portion exits the delivery catheter,
wherein an exterior surface of the expandable anchor is covered by a seal.

US Pat. No. 10,335,272

APPARATUS AND METHOD FOR REPAIRING THE FUNCTION OF A DISEASED VALVE

THE CLEVELAND CLINIC FOUN...

1. An apparatus for repairing the function of a diseased valve, the apparatus comprising:a tubular first support member expandable to a first average diameter and having oppositely disposed proximal and distal first support member ends;
a tubular second support member spaced axially apart from the first support member and expandable to a second average diameter that is smaller than the first average diameter, the second support member having oppositely disposed proximal and distal second support member ends; and
a tubular graft section interconnecting the first and second support members and defining an annulus axially spaced from both the first and second support members, the tubular graft section having oppositely disposed proximal and distal graft section ends axially spaced apart by a graft section body, the proximal graft section end being connected directly to the distal first support member end and the distal graft section end being connected directly to the proximal second support member end, a diameter of the tubular graft section at the proximal graft section end being larger than a diameter of the tubular graft section at the distal graft section end, the graft section overlapping and being secured to an outer surface of one of the first and second support members and the graft section underlying and being secured to an inner surface of the other of the first and second support members.

US Pat. No. 10,335,271

SYSTEMS FOR ASSESSING AND CUTTING PERICARDIAL TISSUE

Edwards Lifesciences Corp...

1. An assembly for assessing and cutting a leaflet of a prosthetic valve from a sheet of bioprosthetic tissue, the assembly comprising:a flat surface on which a sheet of bioprosthetic tissue may be supported;
a die for cutting the leaflet having a plate and a sharp die cutting pattern resembling the leaflet and defining a boundary, an exposed portion of the sharp die cutting pattern depending downward from the plate;
an opening formed in the die within the boundary of the die cutting pattern; and
a distance measurement gauge having a vertically movable probe that passes through the opening for measuring the thickness of the tissue, wherein the opening through the die permits passage of the vertically movable probe of the distance measurement gauge at different locations within the boundary of the die cutting pattern.

US Pat. No. 10,335,270

METHOD AND APPARATUS FOR COMPRESSING/LOADING STENT-VALVES

SYMETIS SA, Ecublens (CH...

1. An apparatus for compressing a transcatheter cardiac stent-valve, the apparatus comprising:a hollow channel having an interior surface shaped for progressively compressing the stent-valve in response to longitudinal advancement of the stent within the hollow channel, the hollow channel comprising at least one slot through a wall thereof; and
a mover comprising a portion fitting outside the circumferential periphery of the hollow channel and a portion slidable in the slot and projecting therethrough for engaging the stent-valve within the hollow channel, for applying to the stent-valve a longitudinal driving force from outside the hollow channel;
wherein the portion of the mover slidable in the slot is shaped as a blade having a thin leading edge or surface that advances within the slot, and a long edge or surface that slides against the edge of the slot.

US Pat. No. 10,335,269

SPEAKING VALVE HAVING A COVER PART FORMED AT LEAST PARTIALLY OF AN ELASTIC MATERIAL

1. A speaking valve for laryngectomy or tracheostomy care comprising: a cover part, a controller, a housing part and a filter, the housing having an upper edge at one end and forming a valve seat at an opposite end, the cover is mounted to the housing to overlap the upper edge of the housing wherein the controller has a closure part spaced apart from the cover part, the entire filter extending between the closure part and the cover part and wherein the closure part cooperates with the valve seat when the speaking valve is moved from an open position into a closed position, wherein the cover part is formed at least partially from an elastic material, wherein an at least partial deformation takes place at least in a region of the cover part when the speaking valve is moved from an open position into a closed position, and wherein the filter is arranged on the controller in such a way that the filter can follow the movement of the controller within the housing between the open position and the closed position.

US Pat. No. 10,335,268

ANTERIOR-POSTERIOR-CAPSULE-ACTUATED HYDRAULIC ACCOMMODATIVE INTRAOCULAR LENSES AND LENS SYSTEMS

1. A biocompatible accommodative hydraulic intraocular lens (AHIOL) system for implantation in the capsule of an eye from which the crystalline lens has been extracted via anterior capsule capsulorhexis, the system comprising:a self-reservoired hydraulic lens and an actuator for the hydraulic lens;
the actuator comprising a coaxial pair of cylinders having an outer cylinder and an inner cylinder in sliding relationship with one another, the outer cylinder comprising an inner ledge and an end configured for contact with one of an anterior and a posterior capsule, the inner cylinder comprising a plurality of substantially axis-parallel slots at one end and an end configured for contact with the other of the anterior and posterior capsule;
the hydraulic lens comprising a fixed focus lens in slideable relationship with respect to an inner actuator and further comprising a plurality of radial tabs at the inner cylinder slots and extending therethrough, an elastically reconfigurable transparent membrane one of fixedly affixed to the ledge and fixedly sandwiched between the ledge and a membrane ring, and a tensional bellows, one end of which is fixedly affixed to the fixed focus lens and the other end to the ledge,
wherein a closed hydraulic fluid chamber is defined by the transparent membrane, the tensional bellows, the fixed focus lens and the ledge, the fluid chamber containing a refractive hydraulic fluid having an index of refraction greater than that of aqueous humor.

US Pat. No. 10,335,267

INTRAOCULAR LENS HAVING PARTLY OVERLAPPING ADDITIONAL OPTICAL ACTIVE SECTORS ON OPPOSITE SIDES

OCULENTIS HOLDING B.V., ...

1. An intraocular lens (1) comprising an optic (3), the optic having first and second sides (3.1, 3.2) and comprising:a first main lens surface (4.1) at the first side (3.1) and a second main lens surface (4.2) at the second side (3.2), the first main lens surface providing a first main lens surface optical power and the second main lens surface providing a second main lens surface optical power,
the first and second main lens surfaces providing a main lens (4) having a main lens optical power to provide distance vision, and a main optical axis (R) defining a radial direction perpendicular to the main optical axis, a tangential direction around the main optical axis and an axial direction along the main optical axis;
a first additional optical active part (6) at the first side (3.1),
the first additional optical active part providing a positive relative optical power with respect to the first main lens surface optical power,
the first additional optical active part (6) being positioned at a distance from the optical axis (R) and in tangential directions being delimited by boundaries extending in radial directions, and
the first additional optical active part (6) overlapping with the second main lens surface (4.2) to form a secondary lens having the positive relative optical power of the first additional optical active part (6) with respect to the main lens (4) to provide near or reading vision;
a central part (8) at the first side (3.1),
the central part being arranged such that the main optical axis (R) passes through the central part, and fitting within a circumscribing circle around the optical axis,
the central part (8) being adjacent to the first additional optical active part (6), and
the central part having a relative optical power between ?2 and 2 diopter with respect to the first main lens surface optical power; and
a second additional optical active part (15) at the second side (3.2),
the second additional optical active part being arranged such that the main optical axis (R) passes through the second additional optical active part, and fitting within a circumscribing circle around the main optical axis (R), and
the second additional optical active part providing a relative optical power and/or an optical aberration with respect to the second main lens surface,
wherein the distance between the main optical axis (R) and the first additional optical active part (6) is smaller than the radius of the circle circumscribing the second additional optical active part (15), the diameter of the circle circumscribing the central part (8) being smaller than the diameter of the circle circumscribing the second additional optical active part (15), such that the second optical active part at least partly overlaps with the first additional optical active part (6) and partly overlaps with the first main lens surface (4.1).

US Pat. No. 10,335,266

FLEXIBLE STRETCH STENT-GRAFT

C. R. Bard, Inc., Murray...

1. A stent device having a relaxed state and an expanded state, the stent device comprising:a stent frame having a central axis, a luminal surface, and an abluminal surface, the stent frame having a plurality of gaps along the abluminal surface providing communication between the abluminal surface and the luminal surface, wherein at least one gap of the plurality of gaps defines a gap length; and
a generally tubular expanded polytetrafluoroethylene (ePTFE) graft member contiguous with at least one of the luminal surface and the abluminal surface of the stent frame, the ePTFE graft member comprising:
an inner ePTFE graft member;
an outer ePTFE graft member bonded to the inner ePTFE graft member through at least some of the plurality of gaps in the stent frame; and
an ePTFE expansion portion to span the at least one gap, the ePTFE expansion portion having a length greater than a length of the at least one gap.

US Pat. No. 10,335,265

RING ON A CLOSED WEB STENT-GRAFT FOR USE IN TIP CAPTURE

Medtronic Vascular, Inc.,...

1. A prosthesis for implantation within a body lumen, the prosthesis being configured for delivery via a catheter having a tip capture mechanism at a distal end thereof, the tip capture mechanism including at least a first tip capture finger and a second tip capture finger, the prosthesis comprising:a tubular graft of a graft material;
a stent coupled to the tubular graft and including a plurality of crowns and a plurality of struts with each crown being formed between a pair of opposing struts, the stent having endmost crowns that are adjacent to and distal of a proximal edge of the tubular graft, wherein the endmost crowns are secured to the graft material of the tubular graft; and
a ring that directly engages the endmost crowns of the stent, wherein the ring includes a plurality of integral sections that collectively form the ring and each integral section extends between two endmost crowns when the stent is in a compressed delivery configuration, and wherein each of a first integral section of the ring and a second integral section of the ring longitudinally extends beyond the proximal edge of the tubular graft as an attachment loop of the prosthesis that is configured to engage the first tip capture finger and the second tip capture finger, respectively, of the catheter when the stent is in the compressed delivery configuration, the first and second integral sections being disposed at opposing locations of the stent, and
wherein each of the first integral section of the ring and the second integral section of the ring do not longitudinally extend beyond the proximal edge of the tubular graft when the stent is in an expanded deployed configuration.

US Pat. No. 10,335,264

VASCULAR GRAFT

Byung Choo Moon, Toronto...

1. An artificial blood vessel, comprising:a cylindrical inner tube having a hollow part formed therein;
an outer tube provided at an outer circumferential surface of the inner tube and surrounding the inner tube so as to form a double tube structure with the inner tube; and
a connecting line formed in circumferential directions of the inner tube and the outer tube to connect the inner tube and the outer tube, wherein the inner tube includes at least a first guide line in an axial direction, and the outer tube includes at least a second guide line in an axial direction and is positioned at a position corresponding to a position of the first guide line.

US Pat. No. 10,335,263

ORGAN FOR TRANSPLANTATION AND ORGAN STRUCTURE

BIOS CO., LTD., Tokyo (J...

1. An organ structure wherein a kidney, a first ureter, a first urinary bladder, a second ureter, and a second urinary bladder are sequentially connected in this order, wherein the first ureter, the first urinary bladder, the second ureter, and the second urinary bladder are derived from an animal.

US Pat. No. 10,335,262

EMBOLIC PROTECTION DEVICES HAVING SHORT LANDING ZONES

Covidien LP, Mansfield, ...

1. An embolic protection device comprising:an elongate host element including a host element distal portion;
an embolic protection element being movable between a collapsed configuration and an expanded configuration, wherein the embolic protection element comprises;
at least one connecting arm having a first end and a second end,
an apposition ring connected to the second end of the at least one connecting arm, wherein when the embolic protection element is deployed in the expanded configuration, the apposition ring is configured to contact a luminal wall of a blood vessel of a patient in a manner that prevents passage of emboli between the embolic protection element and the luminal wall; and
a mesh connected to the apposition ring, wherein the mesh is dimensioned such that when the apposition ring is expanded to a maximum diameter, the mesh has a diameter at least 10 percent larger than the maximum diameter of the apposition ring; and
a flexible tether including a tether proximal end fixed to the host element distal portion and a tether distal end fixed to a proximal end of the embolic protection element, wherein the embolic protection element is connected to the elongate host element through the flexible tether so that the embolic protection device does not include a tip of a guidewire extending through the embolic protection element or distal to the embolic protection element, and wherein the flexible tether is configured to allow the elongate host element to move axially and laterally relative to the embolic protection element over a limited range of motion when the embolic protection element is deployed in the expanded configuration within the blood vessel.

US Pat. No. 10,335,261

VESSEL FILTER AND METHODS FOR USE

Sanford Health, Sioux Fa...

1. An apparatus comprising:a filter; and
a frame having a first end and a second end, wherein the frame includes a first support and a second support each continuously extending from the first end to the second end, wherein the first support is coupled to a first side of the filter and the second support is coupled to an opposite side of the filter, wherein the first support is directly coupled to the second support at the first end of the frame such that the frame and the filter taper to a first pointed tip at the first end of the frame, wherein the first support is directly coupled to the second support at the second end of the frame such that the frame and the filter taper to a second pointed tip at the second end of the frame, wherein the frame and the filter together define a first lumen, wherein the frame has shape memory and is movable between a first position in which the first lumen has a first diameter and a second position in which the first lumen has a second diameter, wherein in the second position, the first support and the second support are arranged spaced apart such that there is a gap between the first support and the second support, wherein the first diameter is smaller than the second diameter, wherein the frame and filter together are configured such that an entire length of the apparatus from the first end of the frame to the second end of the frame is configured to be circumferential to a second lumen of a target vessel in the second position, wherein an entire length of the first lumen defined by the frame and the filter is configured to be substantially concentric with the second lumen of the target vessel in the second position, and wherein the frame has an intermediate position such that the frame and the filter define a cone-shape at the second end of the frame such that the first lumen has the first diameter at the second end of the frame and the first lumen has the second diameter at the first end of the frame when the frame transitions from the second position to the first position.

US Pat. No. 10,335,260

METHODS OF TREATING A THROMBUS IN A VEIN USING CYCLICAL ASPIRATION PATTERNS

Insera Therapeutics, Inc....

1. A method of treating a thrombus in a vein using a repetitive cyclical pattern for aspiration, the method comprising:inserting a distal end of a catheter into the vein, wherein the thrombus is distal to the distal end of the catheter, wherein the thrombus causes acute ischemic stroke due to cerebral venous sinus thrombosis or causes deep vein thrombosis;
choosing the cyclical pattern from a plurality of provided cyclical patterns, the cyclical pattern comprising repetition of a first suction level, a second suction level different than the first suction level, and a third suction level different than the first suction level and the second suction level; and
aspirating the thrombus using negative pressure through the catheter, the negative pressure varying according to the chosen cyclical pattern generated by power electronics of an automated negative suction device.

US Pat. No. 10,335,259

3D FILTER FOR PREVENTION OF STROKE

FRID MIND TECHNOLOGIES, ...

1. An implantable endoluminal prosthesis comprising: a braided framework defining a cylindrical lumen devoid of impermeable membrane, said braided framework being self-expandable, comprising a plurality of layers of wires made of biocompatible material, each layer forming a mesh, the meshes forming a lattice with a plurality of wires of given layers, the lattice defining polygonal opening units when observed normal to a wall of the implantable endoluminal prosthesis, a diameter (?25) of the wires being at least 30 ?m and at most 150 ?m, a mean diameter (?27) of an inscribed circle of the polygonal opening units being at least 75 ?m and at most 200 ?m in a fully expanded state, characterized in that:the braided framework consists of at least 128 and at most 512 wires;
a ratio (T1?25) of a thickness (T1) of a wall of said implantable endoluminal prosthesis to the diameter (?25) of wire is at least 3.0;
in the fully expanded state, a surface coverage ratio (SCR) of said braided framework is more than 50% and less than 90%;
when the implantable endoluminal prosthesis is deployed in a curved lumen having a H/W ratio between 0.5 and 0.9, the mean diameter (?27) of the inscribed circle of opening units is at least 75 ?m and at most 200 ?m, a length-related compression ratio (LCR) being between 15% and 40%, and the surface coverage ratio (SCR) of the braided framework being more than 50% at a side of outer curve.

US Pat. No. 10,335,258

PROSTHESIS FOR REPAIRING A HERNIA DEFECT

C.R. Bard, Inc., Murray ...

1. A prosthesis for repairing a hernia defect, the prosthesis comprising:a patch body having a periphery, a first axis and a second axis perpendicular to the first axis, the first axis and the second axis intersecting at approximately a center of the patch body, a first portion of the patch body on a first side of the first axis and a second portion of the patch body on a second side of the first axis;
a self-expanding hoisting frame releasably attachable to the patch body to assist in spreading the patch body from a reduced configuration to an expanded configuration, the self-expanding hoisting frame including an outer frame component and an inner frame component configured to translate force, the outer frame component defining an open interior and the inner frame component extending through the open interior; and
a tether attached to the inner frame component, a free end of the tether extendable away from the inner frame component and through the patch body when the self-expanding hoisting frame is releasably attached to the patch body, a pulling force on the free end of the tether in an outward direction away from the patch body being directed by the inner frame component in a direction toward the outer frame component when the patch body is in the expanded configuration;
wherein the patch body and the self-expanding hoisting frame when releasably attached to the patch body are manipulable into the reduced configuration for insertion through an opening into a patient; and
wherein the inner frame component is configured to be separated into a plurality of segments to facilitate withdrawal of the self-expanding hoisting frame through the opening when the self-expanding hoisting frame is released from the patch body.

US Pat. No. 10,335,257

THREE-DIMENSIONAL RESORBABLE IMPLANTS FOR TISSUE REINFORCEMENT AND HERNIA REPAIR

Tepha, Inc., Lexington, ...

1. A reinforced absorbable implant comprising:a) a three-dimensional structure comprising an original three dimensional shape comprising a concave and a convex surface configured to contour to a patient's tissue, and monofilament, multifilament fibers or combinations thereof comprising poly-4-hydroxybutyrate (P4HB) or a copolymer thereof, or a porous film comprising P4HB or a copolymer thereof, and
b) a reinforcing material comprising a continuous or interrupted ring of P4HB extrudate at the outlying border of the three-dimensional structure, wherein the implant can be temporarily deformed for implantation and the three dimensional structure unaided assumes its original three-dimensional shape,
wherein the implant has one or more of the following properties:
(i) a suture pullout strength of at least 10 N
(ii) a burst strength of at least 1 Kg;
(iii) pore diameters of at least 50 ?m; and
(iv) a Taber stiffness that is less than 100 Taber stiffness units.